Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
Evaluation of Multifocal Contact [CONTACT_721526]-Blocker on Visual 
Function   Protocol CR-6391  
 Version: 4.0  
                            Date: 12 January 2022   Investigational Products: JJV In vestigational Multifocal Contact [CONTACT_721527]-
Blocker  
Control: ACUVUE
¬Æ OASYS Multifocal Contact [CONTACT_721528]: JJV Investig ational Multifocal, ACUVUE
¬Æ OASYS Multifocal Contact [CONTACT_19550], 
HEV Blocker, Presby[CONTACT_19555], Randomized, senof ilcon A (C3), senofilcon A, Daily Wear 
 Statement of Compliance to protocol, GCP and applicable reg ulatory guidelines: 
This trial will be conducted in co mpliance with the protocol, ISO [ZIP_CODE]:2020,
1 the 
International Council for Harmonization Good Clinical Practice E6(R2) (ICH GCP),2 the 
Declaration of Helsinki,3 and all applicable re gulatory requirements. 
 Confidentiality Statement: This document contains confidential information, which shoul d not be copi[INVESTIGATOR_530], referred to, 
released or published without  written approval from [COMPANY_012] Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee approval and informed consent, or as required by [CONTACT_19543], Federal and State Laws, as app licable. Persons to whom this information is 
disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of [COMPANY_012] Vision 
Care, Inc. Any supplemental information that  may be added to this document is also 
confidential and proprie tary to [COMPANY_012] Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document. 
   
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
TABLE OF CONTENTS  
PROTOCOL TITLE, NUMBER, VERSION AND DATE...................................................... 6 
SPONSOR NAME [CONTACT_71191] ....................................................................................... 6 
MEDICAL MONITOR ............................................................................................................. 6 
AUTHORIZED SIGNATURES ............................................................................................... 7 
CHANGE HISTORY................................................................................................................ 9 
SYNOPSIS ...................................................................................................................... ........ 10
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS
................................................................................................................................................. 16 
1.INTRODUCTION AND BACKGROUND ................................................................... 18 
1.1. Name [CONTACT_126139]............................................. 18 
1.2. Intended Use of Investigational Products ............................................................. 18 
1.3. Summary of Findings from Nonclinical Studies .................................................. 18 
1.4. Summary of Known Risks and Benefits to Human Subjects ............................... 18 
1.5. Relevant Literature Refere nces and Prior Clinical Data Relevant to Proposed 
Clinical Study................................................................................................................. ..... 19
2.STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES ...................................... 20 
2.1. Objectives ............................................................................................................. 20 
2.2. Endpoints .............................................................................................................. 20 
2.3. Hypotheses............................................................................................................ 21 
3.TARGETED STUDY POPULATION ........................................................................... 22 
3.1. General Characteristics ......................................................................................... 22 
3.2. Inclusion Criteria .................................................................................................. 22 
3.3. Exclusion Criteria ................................................................................................. 23 
3.4. Enrollment Strategy .............................................................................................. 24 
4.STUDY DESIGN AND RATIONALE .......................................................................... 24 
4.1. Description of Study Design................................................................................. 24 
4.2. Study Design Rationale ........................................................................................ 25 
4.3. Enrollment Target and Study Duration ................................................................ 25 
5.TEST ARTICLE ALLOCATION AND MASKING ..................................................... 25 
5.1. Test Article Allocation ......................................................................................... 25 
5.2. Masking ................................................................................................................ 26 
5.3. Procedures for Maintaining and Breaking the Masking ....................................... 26 
6.STUDY INTERVENTION ............................................................................................. 27 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
6.1. Identity of Test Articles ........................................................................................ 27 
6.2. Ancillary Supplies/Products ................................................................................. 28 
6.3. Administration of Test Articles ............................................................................ 28 
6.4. Packaging and Labeling ........................................................................................ 28 
6.5. Storage Conditions ............................................................................................... 28 
6.6. Collection and Storage of Samples ....................................................................... 29 
6.7. Accountability of Test Articles ............................................................................. 29 
7.STUDY EVALUATIONS .............................................................................................. 30 
7.1. Time and Event Schedule ..................................................................................... 30 
7.2. Detailed Study Procedures .................................................................................... 31 
VISIT 1 ........................................................................................................................... 31 
VISIT 2 ........................................................................................................................... 36 
FINAL EVALUATION .................................................................................................. 39 
7.3. Unscheduled Visits ............................................................................................... 40 
7.4. Laboratory Procedures .......................................................................................... 41 
8.SUBJECTS COMPLETION/WITHDRAWAL.............................................................. 42 
8.1. Completion Criteria .............................................................................................. 42 
8.2. Withdrawal/Discontinua tion from the Study ........................................................ 42 
9.PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. 43 
9.1. Systemic Medications ........................................................................................... 43 
10.DEVIATIONS FROM THE PROTOCOL .................................................................. 44 
11.STUDY TERMINATION ........................................................................................... 45 
12.PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS .............. 46 
13.ADVERSE EVENTS ................................................................................................... 47 
13.1.Definitions and Classifications ............................................................................. 47 
13.2.Assessing Adverse Events .................................................................................... 49 
13.2.1.Causality Assessment .................................................................................... 49 
13.2.2.Severity Assessment ...................................................................................... 50 
13.3.Documentation and Follow-Up of Adverse Events .............................................. 50 
13.4.Reporting Adverse Events .................................................................................... 51 
13.4.1.Reporting Adverse Events to Sponsor .......................................................... 52 
13.4.2.Reporting Adverse Events to the Respons ible IEC/IRB and Health Authorities
 52 
13.5.Event of Special Interest ....................................................................................... 53 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
13.6.Reporting of Pr egnancy ........................................................................................ 53 
14.STATISTICAL METHODS ........................................................................................ 53 
14.1.General Considerations ......................................................................................... 53 
14.2.Sample Size Justification ...................................................................................... 54 
14.3.Analysis Populations ............................................................................................ 54 
14.4.Level of Statistical Significance ........................................................................... 55 
14.5.Primary Analysis .................................................................................................. 55 
14.6.Secondary Analysis .............................................................................................. 57 
14.7.Other Exploratory Analysis .................................................................................. 59 
14.8.Interim Analysis ................................................................................................... 60 
14.9.Procedure for Handling Missi ng Data and Drop-Outs ......................................... 60 
14.10.Procedure for Reporting Deviati ons from Statistical Plan ................................... 60 
15.DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_1645]/ARCHIVING ................................ 60 
15.1.Electronic Case Report Form/Data Collection ..................................................... 60 
15.2.Subject Record ...................................................................................................... 61 
15.3.Trial Registration on Cl inicalTrials.gov ............................................................... 61 
16.DATA MANAGEMENT............................................................................................. 62 
16.1.Access to Source Data/Document ........................................................................ 62 
16.2.Confidentiality of Information.............................................................................. 62 
16.3.Data Quality Assurance ........................................................................................ 62 
16.4.Data Monitoring Committee (DMC) .................................................................... 62 
17.CLINICAL MONITORING ........................................................................................ 63 
18.ETHICAL AND REGULATORY ASPECTS ............................................................ 63 
18.1.Study-Specific Design Considerations ................................................................. 63 
18.2.Investigator Responsibility ................................................................................... 63 
18.3.Independent Ethics Committee or Ins titutional Review Board (IEC/IRB) .......... 63 
18.4.Informed Consent ................................................................................................. 65 
18.5.Privacy of Personal Data ...................................................................................... 65 
19.STUDY RECORD RETENTION................................................................................ 66 
20.FINANCIAL CONSIDERATIONS ............................................................................ 67 
21.PUBLICATION ........................................................................................................... 67 
22.REFERENCES ............................................................................................................ 67 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) ..... 69 
APPENDIX B: PATIENT INSTRUCTION GUIDE ............................................................. 70 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ......................................... 71 
APPENDIX D:  .................................... 100 
 DETERMINATION OF NEAR ADDITION .................................................... 101 
 LENS FITTING CHARACTERISTICS ............................................................ 107 
 SUBJECT REPORTED OCULAR SYMPTOMS ............................................. 113 
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTION
............................................................................................................................................... 115 
 BIOMICROSCOPY SCALE ............................................................................. 121 
 DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION ..... 127 
APPENDIX E:  OCULAR DOMINANCE .......................................................................... 132 
APPENDIX F:  IRIS COLOR SCALE ................................................................................. 133 
APPENDIX G:  TEST AND CONTROL LENS FITTING GUIDE .................................... 135 
APPENDIX H:  PSYCHOPHYSICAL TESTING ............................................................... 136 
APPENDIX I: GUIDELINES FOR COVID-19 RISK MITIGATION ................................ 142 
PROTOCOL COMPLIANCE INVESTI GATOR(S) SIGNATURE [CONTACT_1783] ........................ 154 
 
LIST OF TABLES 
Table 1:  Detailed Ra ndomization Plan for all Study Visits ................................................... 25 
Table 2: Test Articles ........................................................................................................ ...... 27
Table 3: Ancillary Supplies ................................................................................................... . 28
Table 4: Time and Events ...................................................................................................... . 30
Table 5: Disallowed syst emic medications ............................................................................. 43 
Table 6: Disallowed syst emic antihistamines ......................................................................... 44 
Table 7: Examples of major and minor protocol deviations ................................................... 45 
Table 8:  Descriptive Summaries by E ndpoint and Lens Type: 40-65 years ........... 54 
Table 9: Sample Size and Po wer Estimates by [CONTACT_27759] ....................................................... 54 
 
LIST OF FIGURES 
Figure 1: Study Flowchart ..................................................................................................... . 15
 
 
  
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Study Endpoints Primary endpoints: disab ility glare, halo size (mm), and 
starburst size (mm). 
 Secondary endpoints: two-point thresholds with and without 
403 nm filter; heterochromatic contrast threshold and glare 
discomfort. 
  
Primary and secondary endpoint s will be measured with 
natural, binocular viewing conditions. 
 Other endpoints: Subjec tive ratings of glare discomfort, halo 
and starburst intensity and color perception.  
Study Design This is a single-masked, bilateral, contro lled, randomized, 2x2 
crossover, non-dispensing clin ical trial.  There will be two 
study visits.  Eligible subjects will be randomized and fit into 
one study lens per visit based on the randomization schedule.  
There will be a 7¬±3 days washout between the study visits.  
Additional details of the procedures done at each study visit 
are located at the end of the s ynopsis in the flowchart (Figure 
1). 
Sample Size A total of approximately [ADDRESS_985589] approximately 6-7 months.   
 
Anticipated Study 
Population Healthy male and female volunteers with presby[CONTACT_721529].  Subjects will be 
P\RSLF ZLWK UHIUDFWLYH DVWLJPDWLVP RI ¬î ' DQG DGDSWHGsoft contact [CONTACT_19554].  In addition, an attemp t will be made 
to recruit an e
ven distribution in the following ADD groups:  
+0.75 to +1.25 D, +1.50 to + 1.75 D and +2.00 to +2.50 D.  
	0 
!&$		+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Eligibility Criteria - 
Inclusion Potential subjects must satisfy all of the following criteria to 
be enrolled in the study: 
 Inclusion Criteria following Screening:   1. The subject must read, understand, and sign the 
STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 
2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. 
3. The subject must be at least [ADDRESS_985590] lens wearer 
in both eyes (i.e., worn lenses a minimum of [ADDRESS_985591] 1 month of duration). 
6. The subject must alread y be wearing a presby[CONTACT_721530] (e.g., reading spectacles over contact [CONTACT_13276], multifocal or  monovision contact [CONTACT_13276], 
etc.) or if not respond positively to at least one symptom on the ‚ÄúPresby[CONTACT_391351]‚Äù.  
 
Inclusion Criteria at Baseline Evaluation:  7. The subject must have no rmal color perception as 
evidenced by [CONTACT_5978] [ADDRESS_985592]‚Äôs distance sphe rical equivalent of their 
refraction must be in the range of -1.[ADDRESS_985593]‚Äôs refractive cylinder must be ¬î' in each 
eye. 
10. The subject‚Äôs ADD power must be in the range of 
+0.75 D to +2.[ADDRESS_985594] corrected distance visual 
acuity of 20/20
-3 or better in each eye. 
	0 
!&$	
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Eligibility Criteria ‚Äì 
Exclusion Potential subjects who meet any of the following criteria will 
be excluded from participating in the study: 
 Exclusion Criteria following Screening:  1. Currently pregnant or lactating. 
2. Any systemic disease (e.g., Sj√∂gren‚Äôs Syndrome), 
allergies, infectious diseas e (e.g., hepatitis, tuberculosis), 
contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g., rheumatoid arthritis), or other 
diseases, by [CONTACT_6270]-report, which are known to interfere 
with contact [CONTACT_71171]/ or participation in the study. 
3. 
Use of any of the following oral medications within 1 
week prior to enrollment: oral retinoids, oral tetracyclines, 
oral phenothiazines, antic holinergics, oral/inhaled 
steroids, oral phosphodiesterase type 5 inhibitors, 
interferon alfa, antimycobacterial antibiotics, and 
nitroimidazole antibiotics.  See section 9.1 for additional details regarding excluded systemic medications.  
4. Any current use of ocular medication with the exception 
of rewetting drops. 
5. Any known hypersensitivity or allergic reaction to single 
use preservative free rewetting drops or sodium fluorescein. 
6. Any previous or planned (dur ing the course of the study) 
ocular surgery (e.g., radial keratotomy, PRK, LASIK  dacryocystorhinostomy, cataract  surgery, retinal surgery, 
peripheral iridotomy/iridectomy, etc.). 
7. Participation in a ny contact [CONTACT_93830] 7 days prior to study enrollment. 
8. Employee or immediate family member of an employee of clinical site (e.g., I nvestigator, Coordinator, 
Technician). 
9. Any active or ongoing ocular or  systemic allergies that 
may interfere with c ontact lens wear.   
10. A history of amblyopia, stra bismus or binocular vision 
abnormality. 
11. History of herpetic keratitis. 
12. History of optic nerve or retinal disease or trauma. 
13. Abnormal color vison. 
 
 
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Exclusion Criteria at Baseline Evaluation: 
 
14. Any other ocular abnorma lities that are known to 
interfere with contact [CONTACT_13293] w ear and/or par ticipation in 
the study. This may include, but not be limited to 
entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia, re current styes, glaucoma, 
history of recurrent corneal er osions, or corneal distortion  
15. Any grade 3 or greater slit lamp findings (e.g., edema, 
corneal neovascularization, corneal staining, tarsal 
abnormalities, conjunc tival injection) on the FDA scale . 
16. Any current ocular infection or inflammation. 
Disallowed 
Medications/Interventions  Use of any prescription or over-the-counter (OTC) 
medications that may aff ect contact [CONTACT_13279].  
See Section 9.[ADDRESS_985595] (UADE), or any SAE where relationship to study agent cannot be ruled out, will result in stoppi[INVESTIGATOR_71144].  In th e event of a UADE or SAE, the 
Sponsor Medical Monitor may unmask the treatment regimen 
of subject(s) and may discuss this with the Principal Investigator [INVESTIGATOR_35435]. 
Ancillary Supplies/ Study-Specific Materials Non-preserved rewetting drops and optical bench test methods.  
Principal Investigator(s) 
and Study 
Institution(s)/Site(s) A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the St udy Protocol and is 
included in the study Trial Master File.   
  
 
 
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF 
TERMS 
Add   Near addition; the additional pow er required for near vision correction  
ADE   Adverse Device Effect 
ADHD   Attention Deficit Hyperactivity Disorder 
AE   Adverse Event/Adverse Experience AO1DfA ACUVUE OASYS
¬Æ 1-DAY with HydraLuxe‚Ñ¢ TECHNOLOGY for 
ASTIGMATISM 
AOfA ACUVUE OASYS¬Æ 2-WEEK for ASTIGMATISM 
BSCVA  Best Spectacle Corrected Visual Acuity CFR   Code of Federal Regulations CLUE   Contact [CONTACT_721531]-[ADDRESS_985596] HIV   Human Immunodeficiency Virus IB   Investigator‚Äôs Brochure ICH   International Council for Harmonization IDE   Investigational Device Exemption IEC   Independent Ethics Committee IRB   Institutional Review Board ISO   International Organization for Standardization ITT   Intent-to-Treat JJVC   [COMPANY_012] Vision Care, Inc. LASIK   Laser-Assisted in Situ Keratomileusis LogMAR  Logarithm of Minimal Angle of Resolution OD   Right Eye OS   Left Eye OU   Both Eyes PIG   Patient Instruction Guide PQC   Product Qu ality Complaint 
PRK   Photorefractive Keratectomy PRO   Patient Reported Outcome 
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
QA   Quality Assurance 
SAE   Serious Adverse Event/Serious Adverse Experience SAP   Statistical Analysis Plan SAS   Statistical Analysis System SD   Standard Deviation UADE   Unanticipated Adverse Device Effect [LOCATION_003]DE  Unanticipated Serious Adverse Device Effect VA   Visual Acuity   
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
1. INTRODUCTION AND BACKGROUND 
Filters have long been used in ophthalmic de vices, with sunglasses probably the best-known 
example.  Sunglasses help to minimize the delete rious effects of intense light.  Intense light 
can lead to discomfort as well as degrade visual performance.  Using light filters can help to 
improve the discomfort associated with intense light as well as improve the visual performance.  [COMPANY_012] currently has two multifocal contact [CONTACT_721532].  Multifocal 
contact [CONTACT_721533], where the distance, intermediate and near corrections are placed in front of the pupil at one time.  This 
type of correction can reduce image contrast and create visual artifacts,  thus reducing visual 
performance.  Given the vision compromise cr eated by [CONTACT_721534], the additional 
detrimental impact of intense light  can further compound the problem. 
 The purpose of this study is to investigate the potential visual benefits of using a High Energy Visible (HEV) light blocker in multifocal contact [CONTACT_721535].  An investigational multifocal contact [CONTACT_721536] a multifocal lens without an HEV blocker.     
1.1. Name [CONTACT_721578]:  JJV I nvestigational Multifocal Contact [CONTACT_721537] (Test 
Lens) JJV Investigational Multifocal Contact [CONTACT_721538]-Blocker (Control Lens) 
1.2. Intended Use of Investigational Products 
All lenses in this study are intended to correct  spherical refractive e rror and presby[CONTACT_19555].  The 
study is non-dispensing and all of the study lenses w ill be worn as a daily disposable lens, with 
the lenses being discarded after a wear at the clinical site.  The lenses w ill be fit in a randomized 
fashion.  After fitting, the subject will undergo a number of vision assessments.  The sequence 
will then be repeated with the other study lens type. 
1.3. Summary of Findings fr om Nonclinical Studies 
All previous pre-clinical findings were deemed satisfactory prior to proceeding with clinical 
trials on humans. For the most comprehensiv e nonclinical information regarding the JJV 
investigational lenses used in this study refer to the latest ve rsion of the CR-[ADDRESS_985597] lenses.  A listing of examples of  adverse reactions is found in the Section 13 of 
this protocol.  The investigator should follow normal clinical guidelines regarding examination 
and care of subjects who participate in this tr ial.  Refer to study lens package insert for 
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
The lenses displayed good clinical vision pe rformance with binocular, high luminance, high 
contrast logMAR visual acuity of -0.132, -0.066 and 0.072 at distance, intermediate and near 
respectively.  There were four adverse of events  during the study.  Three of the four were non-
ocular adverse events.  Two of those not rela ted to the study lenses and one (headache) was 
related to the Control Contact [CONTACT_13293].  There was one ocular adverse event (non-significant 
infiltrative event) that was possibly related to the test lens.   
For information about the control product refe r to study lens package insert for additional 
details (APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  and the 
Investigational Brochure (IB) for the Investigational product. 
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES 
2.1. Objectives  
Characterize the effects of an HEV-blocker on several measures of visual function in a 
presby[CONTACT_721539] a lens without an HEV-Blocker 
(ACUVUE¬Æ OASYS Multifocal). 
 
Primary Objective The primary objective is to evaluate the impact an HEV blocker used in a multifocal contact [CONTACT_721540], starbursts and halos.  Secondary Objective  The secondary objective is to assess the impact an HEV blocker has on the deleterious effects 
of scatter, measured as two-point thresholds measured with and without a [ADDRESS_985598] thre shold and glare discomfort. 
 Exploratory Objectives The exploratory endpoints include subjective response to the visual artifacts and color perception.  
2.2. Endpoints  
Primary Endpoints Glare Disability Threshold (change in log relative energy level) (GD) 
GD threshold will be evaluated by [CONTACT_721541] a white light 
annulus (~10-deg inner diameter; 12-degree outer diameter), which surrounds a mid-wave 
(580 nm), central grating target. GD will be  quantified by [CONTACT_721542].  Starburst diameter (mm) 
Starburst diameter will be quantified by [CONTACT_721543] a small, point-like stimulus. A calibrated custom-made micrometer (two sides with reverse threading) will be used to spread two posts out from a central mid-point. The posts attach to a custom-designed ru ler that indicates the lateral spread of the starburst.  
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
Halos (mm) 
Halos will be quantified by [CONTACT_703886] (mm) of outer edges of the halo of the white light point-like stimulus and is measured using the same micrometer as for starbursts.  Secondary Endpoints   Two-point threshold (mm) 
To create the two-point threshold stimulus, a single point-source like stimulus will be spread into two distinct points of light, using a custom-built, collapsible light baffle. The two-point threshold will be quantified as the minimum distance (mm) at which a participant can detect two distinct points of light, sepa rated by a small black space.  
 Glare Discomfort (change in squint in mm) (GDC) 
GDC will be evaluated by [CONTACT_721544]-wave centra l grating target, compared to the maximal 
squint during a 5-second photostress exposure induced by a solid, 10-degree broadband field, which completely obscures the target (~10-deg diameter). Both eyes will be recorded and averaged, to produce an average palpebral fissu re height before and during the photostress 
exposure.  Heterochromic Contrast Threshold (HCT) 
Using the same optical bench se t-up described in GD above, to measure HCT, participants will 
view the mid-wave (580 nm) grating target presented on presented on a short-wave (460 nm) ‚Äúsky-light background.‚Äù The intensity of the back ground will be adjusted, until the participant 
is no longer able to resolve the grating target. The log-relative energy of the background needed to obscure the central target will be recorded as HCT.    Exploratory Endpoints  Color perception testing 
A custom-built device will be used to measur e color perception. Participants will view a 
stimulus that consists of broadba nd light that is passed through in tegrating spheres, coated with 
an ultra-diffuse reflective material. The experimenters will then adjust a set of Wratten filters until the subject perceives a perfect, untinte d white. CIE coordinate s (x,y; u‚Äô,v‚Äô; total 
illuminance; total irradiance) will be recorded.    Subjective discomfort while viewing halos, st arbursts and the photostressor will be assessed. 
Subjective discomfort will be measured using a single Likert -type question following exposure 
to the photostressor and after view ing halo and starburst stimuli.  
2.3. Hypotheses 
Primary Hypotheses  
	0 
!&$
	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
1. Glare disability thresholds measured using the optical bench will be significantly higher 
in the Test lens compared to the Control lens.  
2. Halo sizes (mm) measured with the custom halometer device will be significantly smaller in the Test lens compared to the Control lens.  
3. Starburst size (mm), as measured with the halometer,  will be significantly smaller in the Test lens compared to the Control lens.   
  Secondary Hypotheses  
1. Two-point thresholds (mm) measured using the light shield and baffle device will be significantly lower in the Test lens compared to the Control lens with the 403 nm filter.  
 
2. Two-point thresholds (mm) measured using the light shield and baffle device will be significantly lower in the Test lens compar ed to the Control lens without the [ADDRESS_985599] a si gnificantly lower change in squint response (mm) compared 
to the Control lens with respect to glare di scomfort as measured on an optical bench. 
 
4. Heterochromatic contrast thresholds measured using the optical bench will be significantly higher in the Test lens  compared to the Control lens.  
 
 Exploratory Hypotheses  
 
1. Color appearance (x, y, u‚Äô, v‚Äô) measured usi ng the custom colorimeter device will not 
differ between the Test lens and the Control lens.   
2. The photostressor, halo and starburst stimuli will be perceived as significantly less 
intense / uncomfortable in the Test le ns, compared to the Control lens.  
3. TARGETED STUDY POPULATION 
3.1. General Characteristics  
Healthy male and female volunteers with presby[CONTACT_721545].  Subjects will be adapted soft contact [CONTACT_721546]¬î  75 D).  In addition, an attempt will be made to recruit an even distribution 
of subjects in the following ADD groups: +0.75D  to +1.25 D, +1.50D to +1.75 D and +2.00D 
to +2.[ADDRESS_985600] satisfy all of the fo llowing criteria to be enrolled in the study: 
	0 
!&$

+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 Inclusion Criteria following Screening The subject must: 
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form 
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 
3. Be between at least [ADDRESS_985601] lens wearer in both eyes (i.e., worn lenses a minimum of [ADDRESS_985602] 8 hours per w ear day, for 1 month of more duration). 
6. Be wearing a presby[CONTACT_721547] (e.g., reading spectacles over contact 
[CONTACT_13276], multifocal or monovision contact [CONTACT_13276], etc.) or if not respond positively to at least one symptom on the ‚ÄúPresby[CONTACT_391351]‚Äù.  
Inclusion Criteria at Baseline Evaluation 
7. The subject must have normal color percep tion as evidenced by [CONTACT_5978] [ADDRESS_985603]‚Äôs distance spherical  equivalent of their refracti on must be in the range of -
1.00 D to -4.00 D. 
9. The VXEMHFW¬∂V UHIUDFWLYHF\OLQGHUPXVW EH¬î 'LQ HDFK H\H  
10. The subject‚Äôs ADD power must be in the range of +0.75 D to +2.[ADDRESS_985604] corrected distan ce visual acuity of 20/20-3 or better in each 
eye. 
3.3. Exclusion Criteria 
Potential subjects who meet any of the following criteria will be excluded from participating in the study:   Exclusion Criteria following Screening The subject must not: 
1. Be currently pregnant or lactating. 
2. Any systemic disease (e.g., Sj√∂gren‚Äôs Syndrom e), allergies, infectious disease (e.g., 
hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), 
autoimmune disease (e.g., rheumatoid arthritis), or other diseases, by [CONTACT_6270]-report, which are known to interfere with contact [CONTACT_71171]/or partic ipation in the study. 
3. Use of any of the following oral medications within 1 week prior to enrollment: oral retinoids, oral tetracyclines, oral phenothiazines, anticholiner gics, oral/inhaled steroids, 
oral phosphodiesterase type 5 inhibitors, inte rferon alfa, antimycobacterial antibiotics, 
and nitroimidazole antibiotics.  See S ection 9.1 for additional details regarding 
excluded systemic medications. 
4. Any current use of ocular medication with the exception of rewetting drops. 
5. Any known hypersensitivity or allergic reaction to single use preservative free 
rewetting drops or sodium fluorescein. 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
6. Any previous or planned (during the course  of the study) ocular surgery (e.g., radial 
keratotomy, PRK, LASIK  dacryocystorhinostomy, cataract surgery, retinal surgery, 
peripheral iridotomy/iridectomy, etc.). 
7. Participation in any contact [CONTACT_71170] 7 days prior to study enrollment. 
8. Employee or immediate family member of an employee of clinical site (e.g., 
Investigator, Coordinator, Technician). 
9. Any active or ongoing ocular or systemic allergies that may interfere with contact [CONTACT_94638]. 
10. History of herpetic keratitis.   
11. A history of amblyopia, strabismus or binocular vision abnormality. 
12. History of optic nerve or retinal disease or trauma 
13. Abnormal color vison. 
 Exclusion Criteria at Baseline Evaluation The subject must not have: 
14. Any other ocular abnormalities that are known to interfere with contact [CONTACT_71171]/or participation in the study. This may include, but not be limited to entropi[INVESTIGATOR_2394], 
ectropi[INVESTIGATOR_2394],  chalazia, recu rrent styes, glaucoma, history of  recurrent corneal erosions, or 
corneal distortion  
15. Any grade 3 or greater slit lamp findings  (e.g., edema, corneal neovascularization, 
corneal staining, tarsal abnormalities, conjunctival injection) on the FDA scale. 
16. Any current ocular infection or inflammation.  
3.4. Enrollment Strategy 
Study subjects will be recruited from the Instituti on/clinical site‚Äôs subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved materials.  
4. STUDY DESIGN AND RATIONALE 
4.1. Description of Study Design 
This is a single-site, 2-visit, single-masked (partial), bilateral, c ontrolled, 2x2 crossover, 
randomized, non-dispensing clinical trial.  There will be two study vi sits. Approximately [ADDRESS_985605] s will be fit into the study lenses at each 
visit per the randomization sche me. There will be a 7¬±3 days washout between study visits. 
Subjects will not wear the study lenses outside the study visit.  Additional details of the 
procedures done at each study vis it are contained in Section 7.2. 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
4.2. Study Design Rationale 
Crossover designs are a well-established study design in which subjects are exposed to multiple 
treatments during different time periods.  A 2 √ó[ADDRESS_985606] as their own control to reduce the influence of potential confounding factors such as age, gender and vision correction. A 7¬±[ADDRESS_985607] lens wear sequences in  a bilateral fashion usi ng a 2x2 crossover design 
with a block of size 2. The randomization scheme will be generated using the PROC PLAN 
procedure from Statistical Analysis System (SAS) Software Versi on 9.4 or higher (SAS 
Institute, Cary, NC)
6. Please see below for details regarding the randomization by [CONTACT_6960]. 
 Table 1:  Detailed Randomizati on Plan for all Study Visits 
Sequence Period 1 (Visit 1)   Period 2 (Visit 2)  
[ADDRESS_985608] o ccurred prior to randomization: 
 
x Informed consent has been obtained 
x Subject meets all the inclusion/exclusion criteria 
x Subject history and baseline in formation has been collected 
 When dispensing test articles, the followi ng steps should be followed to maintain 
randomization codes: 
1. Investigator or designee (documented on the Delegation Log) will consult the lens fitting schedule to obtain the test article assignment for that subject prior to dispensing. 
	0 
!&$

+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
2. Investigator or designee will record the subject‚Äôs number on the appropriate line of the 
lens fitting schedule  
3. Investigator or designee will pull the appropr iate test articles fr om the study supply. 
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed outside the clinical site) or not, must be recorded on the Test Article Accountability Log in the ‚ÄúDispensed‚Äù section. 
5.2. Masking 
This is a single masked (partial) study. It is impo ssible to totally mask the subjects as the lenses 
with the HEV blocker will have a different color, however subjects will not be informed of the 
differences in optical designs or any details regarding the intended performance of the HEV 
blocker.  Masking will be used to reduce potential bias. Subjects will be unaware of the identity of the investigational product. Investigators an d clinical site personnel involved in the data 
collection will not be masked as to the identity of the inve stigational product. 
 Under normal circumstances, the mask should not be broken until all subj ects have completed 
the study and the database is finalized. Otherwise, the mask shoul d be broken only if specific 
emergency treatment/course of ac tion would be dictated by [CONTACT_35496]. In such cases, the Investigator may, in  an emergency, contact [CONTACT_7195]. In 
the event the mask is broken, the Sponsor must be informed as soon as possible. The date, 
time, and reason for the unmasking must be documented in the subject record. The Investigator is also advised not to reveal the study treatmen t assignment to the clinical site or Sponsor 
personnel.   Subjects who have had their tr eatment assignment unmasked are expected to return for all 
remaining scheduled evaluations. Subjects who are discontinued may be replaced. 
5.3. Procedures for Maintaining and Breaking the Masking 
The test articles mask shall not be broken unl ess information concerning the lens type is 
necessary for the urgent medical treatment of a subject. The Sponsor must be notified before the mask is broken.  When dispensing test articles, the followi ng steps should be followed to maintain 
randomization codes: 
1. Investigator or designee (documented on the Delegation Log) will consult the lens fitting schedule/randomization sc heme to obtain the test article assignment for that 
subject prior to dispensing. 
2. Investigator or designee will record the subject‚Äôs number on the appropriate line of the randomization scheme. 
3. Investigator or designee will pull the appropr iate test articles fr om the study supply. 
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed outside the clinical site) or not, must be recorded on the Test Article Accountability Log in the ‚ÄúDispensed‚Äù section. 
  
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
6.6. Collection and Stor age of Samples 
When possible, any lens or test article associated with an Adverse Event and/or a Product 
Quality Complaint must be retained and stored in a glass vial with moderate solution pending directions from the sponsor for potential return to JJVC. 
6.7. Accountability of Test Articles 
JJVC will provide the Investigator with suffici ent quantities of study ar ticles and supplies to 
complete the investigation. The I nvestigator is asked to retain all lens shipment documentation 
for the test article accountability records.   Test articles must be ke pt in a locked storage cabinet, accessible only to those assigned by [CONTACT_35500]. The Investigator may delegate this activity to  authorized study site 
personnel listed on the Site Dele gation Log. All test articles must  be accounted. This includes: 
1. What was dispensed for the subject for trial f itting, to wear out of the office, or issued 
for the subject to replace appropriately between visits.  
2. What was returned to the Investigator  unused, including expi [INVESTIGATOR_93785]. 
3. The number and reason for unplanned replacements. 
 The Investigator will collect all unused test article s from the subjects at the end of the subject‚Äôs 
participation. Subject returned unused test articles must be se parated from the clinical study 
inventory of un-dispensed test articles and must be labeled with the subject number and date 
of return. Following final reconciliation of test articles by [CONTACT_2037], the Investigator or monitor will return all unus ed test articles to JJVC . 
 If there is a discrepancy between the shipment  documents and the contents, contact [CONTACT_35501] . 
 Reference : Site Instructions for Test Article Receipt and Test Article Accountability for additional information.      
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
8. SUBJECTS COMPLETION/WITHDRAWAL  
8.1. Completion Criteria 
Subjects are considered to have  completed the study if they:  
x provided informed consent. 
x they are eligible. 
x completed all visits through the final visit 2.   
8.2. Withdrawal/Discontinua tion from the Study 
A subject will be withdrawn from the study for any of the following reasons: 
x Subject withdrawal of consent. 
x Subject not compliant to protocol . 
x Subject lost to follow-up. 
x Subject no longer meets eligibility criteri a (e.g., the subject becomes pregnant). 
x Subject develops significant or serious adverse events necessitating discontinuation of 
study lens wear  
x Subjects who have experienced a Corneal Infiltrative Event (CIE). 
x Investigator‚Äôs clinical judgment regarding the subject safety reasons (that it is in the 
best interest of the subject to stop treatment). 
x Subject missed any study visits   
x Subject not compliant with study lens wear schedule  
x Subject not successfully dispensed due to lack of efficacy and safety including poor 
vision, poor comfort or unacceptable fit. 
 
For discontinued subjects, the Investigator will: 
x Complete the current visit (scheduled or unscheduled). 
x Complete the Final Evaluation, indicating th e reason that the subject was discontinued 
from the study. 
x Record the spherocylindrical refraction with best corrected distance visual acuity. 
x Collect used test article(s) (worn or brought to the visit) from the subject and discard 
them, unless otherwise stated in section 7.2. 
x Collect all unused test article(s) from the subject. 
x Make arrangements for subject care, if needed, due to their study participation 
 
Additional subjects will  be enrolled if a subject discon tinues from the study prematurely.  
 In cases where a subject is lost to follow-up, ever y possible effort must be made to contact [CONTACT_35508]/withdrawal. The measures taken to follow 
up must be documented including two written attempts and a certified letter (or equivalent) as 
the final attempt.  
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Should the study be terminated (either prematurely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as  required by [CONTACT_35512]. 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS 
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness or performance of test articles after they have been released for clinical trial use.    Potential complaints may come from a variety of sources including but not limited to subjects, clinical research associates (CRA), clinical  operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality complaints: 
x Subject satisfaction inquiries reported via ‚ÄúSubjectiv e Questionnaires‚Äù and ‚ÄúPatient 
Reported Outcomes (PRO).‚Äù 
x Clinical test articles that are stored improperly or damaged after receipt at the investigational site. 
x Lens replacements that occur due to drops/fall-outs. 
x Damage deemed by [CONTACT_35513], 
and not indicative of a quality deficiency (i.e., tears, rips, etc.), only in situations where 
there is no deficiency alleged by [CONTACT_423]. 
 
Within [ADDRESS_985609] be 
recorded in the EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use is not configured to send automatic notificati ons or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.   
 Upon receipt of the EDC notification, the COM/ CRA will contact [CONTACT_19568]:  
x Date the complaint was received/recorde d in the EDC System (Date of Sponsor 
Awareness). 
x Who received the complaint? 
x Study number. 
x Clinical site information (contact [CONTACT_2300], site ID, telephone number). 
x Lot number(s). 
x Unique Subject Identifier(s). 
x Indication of who first observed co mplaint (site personnel or subject). 
x OD/OS indication, along with whet her the lens was inserted. 
x Any related AE number if applicable. 
x Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, resolution of symptoms, etc.). 
x Eye Care Provider objective (slit lamp) findings if applicable. 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
x Confirmation of product availa bility for return (and tracking information, if available), 
or rationale if product is not available for return (Ref er to Form Control No.  
for test article return instructions). 
 
Once a complaint is received, it will be assessed by [CONTACT_19569], CRA, or trained site personnel to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or traine d site personnel will follo w Section 13 of this 
protocol. If the AE/SAE was potentially the result of a product quality related deficiency, these procedures also applies and will be executed in parallel.    In some cases, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the PQC forms will be marked ‚ÄúIntentionally Left Blank‚Äù or ‚ÄúILB‚Äù.  Justification for ILB must be documented. 
13. ADVERSE EVENTS 
13.1. Definitions and Classifications 
Adverse Event (AE) ‚Äì An AE is ‚Äúany untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investig ational medical device.‚Äù  
Note : This definition includes events related to the investigational me dical device or the 
comparator, and to the procedures involved. Fo r users or other persons, this definition is 
restricted to events related to investigational medical devices.1 
 
An AE includes any condition (including a pre-existing condition) that: 
1. Was not present prior to the study, but app eared or reappeared following initiation of 
the study. 
2. Was present prior to the study but worsened  during the study. This would include any 
condition resulting from concomita nt illnesses, reactions to  concomitant medications, 
or progression of disease states. 
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immedi ately upon learning of the event. 
 Serious Adverse Event (SAE) ‚Äì An SAE is any adverse event that led to any of the following: 
x Death 
x Serious deterioration in the health of the subject that resulted in any of the following: 
x Life-threatening illness or injury 
x Permanent or persistent impairment of a body structure or a body function 
x Hospi[INVESTIGATOR_93790] 
x Medical or surgical intervention to prev ent life-threatening illness or injury or 
permanent impairment to a body structure or a body function. 
x Chronic disease 
x Foetal distress, foetal death or a congenital physical or mental impairment of birth 
defect. 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to: 
x Microbial Keratitis (MK) 
x Iritis (including cells in the anterior chamber) 
x Permanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines 
or greater 
x Central Corneal Opacity 
x Central Corneal Neovascularization 
x Uveitis 
x Endophthalmitis 
x Hypopyon 
x Hyphemia 
x Penetration of Bo wman‚Äôs Membrane 
x Persistent Epi[INVESTIGATOR_32958] 
x Limbal cell Damage leading to Conjunctivalization 
 Significant Adverse Events  ‚Äì are defined as events that are symptomatic and warrant 
discontinuation (temporary or perman ent) of the contact [CONTACT_197547], but 
not limited to the following: 
x Contact [CONTACT_32985] (CLPU) 
x Significant Infiltrative Events (SIE) 
x Superior Epi[INVESTIGATOR_19532] (SEALs) 
x Any Temporary Loss of > [ADDRESS_985610] lens related corneal events - e.g., Epi[INVESTIGATOR_35450] (EKC) 
x Asymptomatic Corneal Scar 
x Any corneal event which necessitates te mporary lens discontinuation > 2 weeks 
 Non-Significant Adverse Events  ‚Äì are defined as those events that are usually asymptomatic 
and usually do not warrant discon tinuation of contact [CONTACT_35517] a reduction in 
wear time.  However, the Investigator may choos e to prescribe treatment as a precautionary 
measure.    Diagnoses and conditions that are considered Ocular Non-Significant Adverse Events include, 
but not limited to the following: 
x Non-significant Infiltrative Event (NSIE) 
x Contact [CONTACT_19573][INVESTIGATOR_19534] (CLPC) 
x Superficial Punctate Keratitis (SPK) 
x Conjunctivitis: Bacterial, Viral, Allergic 
x Ble
pharitis 
x Meibomianitis 
x Contact [CONTACT_32984] 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
x Localized Allergic Reactions 
x Any corneal event not explicitly defined as serious or significant adverse event, which 
necessitates temporary lens discontinuation < [ADDRESS_985611] (ADE) ‚Äì An ADE is an ‚Äúadverse event related to the use of an 
investigational medical device.‚Äù 
NOTE 1: This definition includes adverse events resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or operation, or 
any malfunction of the inve stigational medical device. 
NOTE 2: This definition includes any event resulting from use error or from intentional 
misuse of the investigational medical device.[ADDRESS_985612] (UADE) ‚Äì A UADE is any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated with, the test 
article, if that effect, problem,  or death was not previously id entified in nature , severity, or 
degree of incidence in the investigational plan, Investigator‚Äôs Brochure or protocol, or any other unanticipated serious problem associated with the test article that relates to the rights, safety and welfare of subjects. 
13.2. Assessing Adverse Events 
In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are categorized correctly. Elements of categorization will include: 
x Seriousness/Classifications (s ee definition in Section 13.1). 
x Causality or Relatedness ‚Äì i.e., the relationship between the test article, study treatment or study procedures and the adverse even t (not related, unlikely related, possibly 
related, or related ‚Äì see definition in Section 13.2.1). 
x Adverse Event Severity ‚Äì Adverse event seve rity is used to assess the degree of 
intensity of the adverse event (mild, modera te, or severe ‚Äì see definition in Section 
13.2.2). 
x Outcome ‚Äì not recovered or not resolve d, recovering or resolving, recovered or 
resolved with sequelae, recovered or reso lved, death related to adverse event, or 
unknown. 
x Actions Taken ‚Äì none, temporar ily discontinued, permanently  discontinued, or other. 
13.2.1. Causality Assessment 
Causality Assessment ‚Äì A determination of the relationshi p between an adverse event and the 
test article. The test article relationship for each adverse event should be determined by [CONTACT_19575]: 
x Not Related- An adverse event that is not re lated to the use of the test article, study 
treatment or study procedures. 
x Unlikely Related ‚Äì An adverse event for which an alternative explanation is more likely, e.g., concomitant treatment, concomitant disease(s), or the relationship of time 
suggests that a causal relationship is not likely. 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
x Possibly Related ‚Äì An adverse event that might be due to the use of the test article, or 
to the study treatment or study procedur es. An alternative explanation, e.g., 
concomitant treatment, concomitant disease(s), is inconclusive. The relationship in 
time is reasonable. Therefore, the causal relationship cannot be excluded. 
x Related ‚Äì An adverse event that is listed as a possible adverse effect (device) or adverse reaction (drug) and cannot be reasonably e xplained by [CONTACT_4867], e.g., 
concomitant treatment of concomitant disease(s). The relationship in time is very suggestive, e.g., it is confirmed by [INVESTIGATOR_5328]-challenge and re-challenge. 
13.2.2. Severity Assessment 
Severity Assessment ‚Äì A qualitative assessment of the degree of intensity of an adverse event 
as determined by [CONTACT_19577]/her by [CONTACT_423]. The assessment of severity is made irrespective of  test article, study tr eatment or study procedure relationship or 
seriousness of the event and should be eval uated according to the following scale: 
x Mild ‚Äì Event is noticeable to the subject but is easily tolerated and does not interfere with the subject‚Äôs daily activities. 
x Moderate ‚Äì Event is bothersome, possibl e requiring additiona l therapy, and may 
interfere with the subject‚Äôs daily activities. 
x Severe ‚Äì Event is intolerable, necessitates additional therapy or alteration of therapy and interferes with the subject‚Äôs daily activities. 
13.3. Documentation and Follow-Up of Adverse Events 
The recording and documenting of adverse even ts (ocular and non-ocular) begin when the 
subjects are exposed to the test article, study tr eatment or study procedure.  Adverse events 
reported before the use of test  article, start of st udy treatment, or study procedures will be 
recorded as medical history. However, if the c ondition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untoward medical events reported after the subject‚Äôs exit from the study will be recorded as adverse ev ents at the discretion of the Investigator. 
 Upon finding an adverse event, the Principal In vestigator will document the condition in the 
subject record and in the eCRFs and complete the Adverse Event eCRF.    Complete descriptions of all adverse events must be available in the subject record. All Adverse Events including local and systemic re actions not meeting the criteria for ‚Äúserious 
adverse events‚Äù shall be captured on the appropriate case report form or electronic data system. All adverse events occurring while the subject  is enrolled in the study must be documented 
appropriately regardle ss of relationship.   
 It is the Investigator‚Äôs responsibility to maintain documentation of each reported adverse event. All adverse events will be followed in accordance with applicable licensing requirements. Such 
documentation will include the following: 
x Adverse event (diagnosis not symptom). 
x Drawings or photographs (where appropri ate) that detail the finding (e.g., size, 
location, and depth, etc.). 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
x Date the clinical site was notified. 
x Date and time of onset. 
x Date and time of resolution. 
x Adverse event classification, se verity, and relationship to te st articles, as applicable. 
x Treatment regimen instituted (where appropriate), including concomitant medications 
prescribed, in accordance with applicable licensing requirements. 
x Any referral to another hea lth care provider if needed. 
x Outcome, ocular damage (if any). 
x Likely etiology. 
x Best corrected visual acuity at the discovery of the ev ent and upon conclusion of the 
event, if the AE is related to the visual system. 
 Upon discovery of an AE that is deemed ‚Äòpossibl y related‚Äô or ‚Äòrelated‚Äô to the test article or 
study procedures (whether related to the visual  system or not), an AE review form ( ) 
must be completed. Additiona l dated and initialed entries should be made at follow-up 
evaluations. Separate forms must be completed for each eye if the AE is bilateral.  
 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature. If cultures are collected, the date of culture collection and laboratory utilized will be recorded.   Changes in the severity of an AE shall be documented to allo w an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as intermittent require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. Changes in the assessment of relationship to the Test Ar ticle shall also be clearly documented. 
 Subjects who present with an adverse event sh all be followed by [CONTACT_737], within 
licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or been satisfactorily resolved. If further treatme nt beyond licensure is required, the patient will 
be referred to the appropriate health care provider. The Investigator will use his/her clinical judgment as to whether a subject reporting with an adverse event will continue in the study. If a subject is discontinued from the study, it will be  the responsibility of the Investigator to 
record the reason for discontinuation. The Inves tigator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse events related to the test artic le, study treatment or study procedur es, as of the final study visit 
date, should be followed to resolu tion of the adverse event or un til referral to an appropriate 
health care provider, as recommended by [CONTACT_737]. Non-ocular adverse events that are not related to the test artic le, study treatment, or study proc edures may be recorded as 
‚Äúongoing‚Äù without further follow-up. 
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by e-mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for an y serious /significant 
adverse events, and 2 days from discovery for any non-significant adverse event. In addition, 
	0 
!&$
	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
a written report will be submitted by [CONTACT_079] [INVESTIGATOR_35451]/IRB according to 
their requirements (Section 13.4.2) . The report will comment whether the adverse event was 
considered to be related to the test ar ticle, study treatment or study procedures. 
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events The Investigator will inform the sponsor of a ll serious/significant adve rse events occurring 
during the study period as soon as possible by e- mail or telephone, but no  later than [ADDRESS_985613] igator is obligated to pursue and obtain 
information requested by [CONTACT_35519]. All 
subjects experiencing a serious/si gnificant adverse event must be  followed up and all outcomes 
must be reported.  When medically necessary, the Investigator ma y break the randomizati on code to determine 
the identity of the treatment that the subject received. The Sponsor and study monitor should be notified prior to unmas king the test articles. 
 In the event of a serious/significant adverse event, the Investigator must: 
x Notify the Sponsor immediately. 
x Obtain and maintain in the subject‚Äôs records all pertinent medical information and medical judgment for colleague s who assisted in the treatment and follow-up of the 
subject. 
x Provide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test article. 
x Notify the IEC/IRB as required by [CONTACT_35520] C/IRB reporting procedure according to 
national regulations. 
 
Unanticipated (Serious) Adverse Device Effect (UADE) In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
than [ADDRESS_985614] report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within [ADDRESS_985615]. 
 Non-Serious Adverse Events All non-serious adverse events, including non-seri ous adverse device effects, will be reported 
to the sponsor by [CONTACT_35521] 2 days from discovery. 
13.4.2. Reporting Adverse Events to the Respon sible IEC/IRB and Health Authorities 
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB‚Äôs written guidelines. Each clinical site will refer to and follow any guidelines set forth 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
by [CONTACT_19581]/IRB. Each clinical site wi ll refer to and follow any guidelines set forth 
by [CONTACT_19582]. 
The Sponsor will report applicable Adverse Events  to the local health authorities according to 
the written guidelines, including reporting timelines.  
13.5. Event of Special Interest 
None. 
13.6. Reporting of Pregnancy 
Subjects reporting pregnancy (by [CONTACT_6270]-report) during the study will be discontinued after the event is recorded as an Adverse Event. Once  discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact [CONTACT_19583], but due to 
general concerns relating to pre gnancy and contact [CONTACT_19584]. Sp ecifically, pregnant women are 
discontinued due to fluctuations in refractive error and/or visual  acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus. 
14. STATISTICAL METHODS 
14.1. General Considerations 
Statistical Analyses will be undertaken by [CONTACT_35522]. A 
general description of the statistical methods to be  implemented in this c linical trial is outlined 
below.   All data summaries and statistical analyses will be performed using the Statistical Analysis System (SAS) software Version 9.4  or  higher (SAS Institute, Cary, NC).
[ADDRESS_985616]/eye will be used when available for summarization and statistical analysis.  Unscheduled visits will be summarized separately and will be excluded from the statistical analysis.  Summary tables (descriptive statistics and/or frequency tables) will be provided for all baseline variables, efficacy variables and safety variab les as appropriate. Con tinuous variables will be 
summarized with descriptive statistics (n, mean, standard deviation (SD), median, minimum and maximum). Frequency count and percentage of subjects or eyes within each category will be provided for categorical data.  Summaries will be presented by [CONTACT_721548], Test (Investiga tional Multifocal Contact [CONTACT_19550]-
MF (HEV) and Control (Investigational Multifocal Contact [CONTACT_19550]-MF) and will be performed separately by [CONTACT_19587]  (Safety Population, Per-Proto col Population and Intent-to-
Treat Population, when appropriate).  All primary and secondary analyses will be pe rformed on the Intent-to- Treat Population (see 
Section 14.3 for additional details).  
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
All subjects who are administered any test ar ticle excluding subjects who drop out prior to 
administering any test article. At least one observation should be recorded. 
 Per-Protocol Population:  All subjects who successfully complete all visits and do not substantially deviate from the protocol as determined by [CONTACT_89632]. 
Justification for the exclusion of subjects with protocol de viations from the per-protocol 
population set will be documen ted in a memo to file. 
 
Intent-to-Treat (ITT) Population: All subjects regardless of actua l treatment and subse quent withdrawal from study or deviation 
from protocol.  At least one obser vation should be recorded.    
14.4. Level of Statisti cal Significance 
Primary and secondary hypotheses will be test with a two-sided type I error rate of 5%. All 
primary and secondary hypothese s must be met in order to test any exploratory hypotheses 
14.5. Primary Analysis  
  Starbursts (mm) and Halos (mm) 
Starbursts and Halos will be analyzed separately using a linear mixed model. Sequence of lens wear, period and lens type will be included as fixed effects.  ADD Power, gender, race and 
dominant eye (Left or Right) may be included in the model as covariates when appropriate. 
Residual errors between measurements within the same subject across study periods will be 
modeled using an unstructured covariance stru cture (UN). The Kenward and Roger Method 
will be used for the denominator degrees of freedom. Comparisons between the study lenses 
will be carried out using two-sided 95% CIs for the least-square mean (LSM) difference (Test minus Control).  Superiority will be declared if the upper limit of the 95% confidence interval 
is below 0.   The model will be constructed as follows:  
We denote ›ï
‡Øú‡Øù‡Øû‡Øü as the Starburst (or Halo) measurement for the lth subject in the assigned to 
the kth lens sequence during the jth period for the ith study lens (Test or Control). 
 
The Model was as follows:  
›ï
‡Øú‡Øù‡Øû‡Øü= ﬂ§‡¨¥+  ﬂö‡¨µ›è›ä›Å‹Æ‡Øú‡Øù‡Øû+ ﬂö‡¨∂›Ä›ã›Ö›é›Å‹≤ ‡Øù+ ﬂö‡¨∑›Å‹ø›ä›Å›ë›ç›Å‹µ ‡Øû + ﬂù‡Øú‡Øù‡Øû‡Øü 
 
x ﬂ§‡¨¥: overall intercept; 
x ›è›ä›Å‹Æ‡Øú‡Øù‡Øû: Lens indicator; ›è›ä›Å‹Æ‡Øú‡Øù‡Øû=[ADDRESS_985617] and 0 otherwise;  
x ›Ä›ã›Ö›é›Å‹≤ ‡Øù  : effect of the ›Üth period; period=1 if analysis period=1 and 0 otherwise 
x ﬂù‡Øù‡Øû‡Øü: random error associated with the ›Üth period for the lth subject for the ith 
treatment assigned to the kth lens sequence   
	0 
!&$

+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
x ·âÇﬂù‡¨µ‡Øû‡Øü
ﬂù‡¨∂‡Øû‡Øü·âÉ‹∞·âÜ·âÇ
·âÉ·âàﬂ™‡¨µ‡¨µ‡¨∂ﬂ™‡¨µ‡¨∂
ﬂ™‡¨∂‡¨µﬂ™‡¨∂‡¨∂‡¨∂·ââ·âá
 
 Hypothesis Testing 
The null and alternative hypotheses are as follows and will be conducted separately for both 
starbursts and halos :   
‹™
‡Øàﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü‡µí 
‹™‡Æ∫ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü	 
 
where ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øüis the population mean difference between the Test and the Control 
lenses. If the upper limit of the 95% confidence limit is below [ADDRESS_985618] 
lens. If the lower limit of the 95% confidence limit is above 0 then the results favor the Control 
lens. 
 GD Threshold (change in log relative energy level) 
GD Threshold will be analyzed using a linear mixed model. Sequence of lens wear, period and lens type will be included as fixed effects.  ADD Power, gender, race and dominant eye (Left 
or Right) may be included in the model as covariates when appropriate. Residual errors between measurements within the same subject  across study periods will be modeled using an 
unstructured covariance structur e (UN). The Kenward and Roger Method will be used for the 
denominator degrees of freedom. Comparisons between the study lenses will be carried out 
using two-sided 95% CIs for the least-square mean (LSM) difference (Test minus Control).  
Superiority will be declared if the upper limit of the 95% confidence interval is below 0.   The model will be constructed as follows:  
We denote ›ï
‡Øú‡Øù‡Øû‡Øü as the GD threshold for the lth subject in the assigned to the kth lens sequence 
during the jth period for the ith study lens (Test or Control). 
 
The Model was as follows:  
›ï
‡Øú‡Øù‡Øû‡Øü= ﬂ§‡¨¥+  ﬂö‡¨µ›è›ä›Å‹Æ‡Øú‡Øù‡Øû+ ﬂö‡¨∂›Ä›ã›Ö›é›Å‹≤ ‡Øù+ ﬂö‡¨∑›Å‹ø›ä›Å›ë›ç›Å‹µ ‡Øû + ﬂù‡Øú‡Øù‡Øû‡Øü 
 
x ﬂ§‡¨¥: overall intercept; 
x ›è›ä›Å‹Æ‡Øú‡Øù‡Øû: Lens indicator; ›è›ä›Å‹Æ‡Øú‡Øù‡Øû=[ADDRESS_985619] and 0 otherwise;  
x ›Ä›ã›Ö›é›Å‹≤ ‡Øù  : effect of the ›Üth period; period=1 if analysis period=1 and 0 otherwise 
x ﬂù‡Øù‡Øû‡Øü: random error associated with the ›Üth period for the lth subject for the ith 
treatment assigned to the kth lens sequence   
x ·âÇﬂù‡¨µ‡Øû‡Øü
ﬂù‡¨∂‡Øû‡Øü·âÉ‹∞·âÜ·âÇ
·âÉ·âàﬂ™‡¨µ‡¨µ‡¨∂ﬂ™‡¨µ‡¨∂
ﬂ™‡¨∂‡¨µﬂ™‡¨∂‡¨∂‡¨∂·ââ·âá
 
 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Hypothesis Testing 
The null and alternative hypotheses for glare disability are as follows:  
 
‹™‡Øàﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü‡µë 
‹™‡Æ∫ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü
 
 
where ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øüis the population mean difference between the Test and the Control 
lenses. If the upper limit of the 95% confidence  limit is below 0 then the results favor the 
Control lens . If the lower limit of the 95% confidence limit is above [ADDRESS_985620] lens. 
 
Note: Prior to fitting any linear models for any endpoint s, the distribution of each endpoint will be 
assessed to ensure the assumption of normality is fulfilled, this will be evaluated using the Shapi[INVESTIGATOR_2152]-Wilks test for each study lens sepa rately under the UNIVARIATE PROCEDURE in 
SAS Version 9.4. If an endpoint is concluded to follow a non-normal distribution, then a generalized linear model will be fit instead of the proposed linear models. If this occurs, the 
distribution that best fits the data will be chosen for the model and associated endpoint.   
 
14.6. Secondary Analysis  
Light Scattering with and without 403nm filer and Glare Discomfort (mm)   
Light scattering with and without a 403nm filt er and glare discomfort will be analyzed 
separately using a linear mixed model. Sequence of lens wear, period and lens type will be included as fixed effects. ADD Power, gender, race and dominant eye (Left or Right) may be 
included in the model as covariates when appr opriate. Residual errors between measurements 
within the same subject across study periods will be modeled using an unstructured covariance 
structure (UN). The Kenward and Roger Method will be used for the denominator degrees of freedom. Comparisons between the study lenses will be carried out us ing two-sided 95% CIs 
for the least-square mean (LSM) difference (Test minus Control).  Superiority will be declared if the upper limit of the 95% conf idence interval is below 0.  
 The model will be constructed as follows:  
We denote ›ï
‡Øú‡Øù‡Øû‡Øü as the Light scattering (with or w ithout 403nm filter) measurement for the lth 
subject in the assigned to the kth lens sequence during the jth period for the ith study lens (Test 
or Control). 
 The Model was as follows:  
›ï
‡Øú‡Øù‡Øû‡Øü= ﬂ§‡¨¥+  ﬂö‡¨µ›è›ä›Å‹Æ‡Øú‡Øù‡Øû+ ﬂö‡¨∂›Ä›ã›Ö›é›Å‹≤ ‡Øù+ ﬂö‡¨∑›Å‹ø›ä›Å›ë›ç›Å‹µ ‡Øû + ﬂù‡Øú‡Øù‡Øû‡Øü 
 
x ﬂ§‡¨¥: overall intercept; 
x ›è›ä›Å‹Æ‡Øú‡Øù‡Øû: Lens indicator; ›è›ä›Å‹Æ‡Øú‡Øù‡Øû=[ADDRESS_985621] and 0 otherwise;  
x ›Ä›ã›Ö›é›Å‹≤ ‡Øù  : effect of the ›Üth period; period=1 if analysis period=1 and 0 otherwise 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
x ﬂù‡Øù‡Øû‡Øü: random error associated with the ›Üth period for the lth subject for the ith 
treatment assigned to the kth lens sequence   
x ·âÇﬂù‡¨µ‡Øû‡Øü
ﬂù‡¨∂‡Øû‡Øü·âÉ‹∞·âÜ·âÇ
·âÉ·âàﬂ™‡¨µ‡¨µ‡¨∂ﬂ™‡¨µ‡¨∂
ﬂ™‡¨∂‡¨µﬂ™‡¨∂‡¨∂‡¨∂·ââ·âá
 
Hypothesis Testing 
The null and alternative hypotheses are as follows and will be conducted separately for both 
starbursts and halos :   
‹™
‡Øàﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü‡µí 
‹™‡Æ∫ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü	 
 
where ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øüis the population mean difference between the Test and the Control 
lenses. If the upper limit of the 95% confidence limit is below [ADDRESS_985622] 
lens. If the lower limit of the 95% confidence limit is above [ADDRESS_985623] Threshold (HCT) 
HCT will be analyzed using a linear mixed model. Sequence of lens wear, period and lens type will be included as fixed effects. ADD Power, gender, race and dominant eye (Left or Right) 
may be included in the model as covariates  when appropriate. Re sidual errors between 
measurements within the same subject across study periods will be modeled using an unstructured covariance structur e (UN). The Kenward and Roger Method will be used for the 
denominator degrees of freedom. Comparisons between the study lenses will be carried out 
using two-sided 95% CIs for the least-square mean (LSM) difference (Test minus Control).  
Superiority will be declared if the upper limit of the 95% confidence interval is below 0.   The model will be constructed as follows:  
We denote ›ï
‡Øú‡Øù‡Øû‡Øü as the HCT measurement for the lth subject in the assigned to the kth lens 
sequence during the jth period for the ith study lens (Test or Control). 
 
The Model was as follows:  
›ï
‡Øú‡Øù‡Øû‡Øü= ﬂ§‡¨¥+  ﬂö‡¨µ›è›ä›Å‹Æ‡Øú‡Øù‡Øû+ ﬂö‡¨∂›Ä›ã›Ö›é›Å‹≤ ‡Øù+ ﬂö‡¨∑›Å‹ø›ä›Å›ë›ç›Å‹µ ‡Øû + ﬂù‡Øú‡Øù‡Øû‡Øü 
 
x ﬂ§‡¨¥: overall intercept; 
x ›è›ä›Å‹Æ‡Øú‡Øù‡Øû: Lens indicator; ›è›ä›Å‹Æ‡Øú‡Øù‡Øû=[ADDRESS_985624] and 0 otherwise;  
x ›Ä›ã›Ö›é›Å‹≤ ‡Øù  : effect of the ›Üth period; period=1 if analysis period=1 and 0 otherwise 
x ﬂù‡Øù‡Øû‡Øü: random error associated with the ›Üth period for the lth subject for the ith 
treatment assigned to the kth lens sequence   
x ·âÇﬂù‡¨µ‡Øû‡Øü
ﬂù‡¨∂‡Øû‡Øü·âÉ‹∞·âÜ·âÇ
·âÉ·âàﬂ™‡¨µ‡¨µ‡¨∂ﬂ™‡¨µ‡¨∂
ﬂ™‡¨∂‡¨µﬂ™‡¨∂‡¨∂‡¨∂·ââ·âá
 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Hypothesis Testing 
The null and alternative hypotheses for HCT are as follows:  
 
‹™‡Øàﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü‡µë 
‹™‡Æ∫ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü
 
 
where ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øüis the population mean difference between the Test and the Control 
lenses. If the upper limit of the 95% confidence  limit is below 0 then the results favor the 
Control lens . If the lower limit of the 95% confidence limit is above [ADDRESS_985625] lens. 
 
14.7. Other Exploratory Analysis  
Color Appearance (white point) 
The four chromaticity coordinates ( ›î›î ,›ï›ï ,›ë›ë∆ç DQG›í›í∆ç IURP WKH FRORU DSSHDUDQFH WHVW ZLOO
be analyzed using a linear mixed model. Sequence of lens wear, period and lens type will be 
included as fixed effects. ADD Power, gender, race and dominant eye (Left or Right) may be 
included in the model as covariates when appr opriate. Residual errors between measurements 
within the same subject across study periods will be modeled using an unstructured covariance 
structure (UN). The Kenward and Roger Method will be used for the denominator degrees of freedom. Comparisons between the study lenses will be carried out us ing two-sided 95% CIs 
for the least-square mean (LSM) difference (Test minus Control).  Superiority will be declared if the upper limit of the 95% conf idence interval is below 0.  
 The model will be constructed as follows:  
We denote ›ï
‡Øú‡Øù‡Øû‡Øü as the Light scattering (with or w ithout 403nm filter) measurement for the lth 
subject in the assigned to the kth lens sequence during the jth period for the ith study lens (Test 
or Control). 
 The Model was as follows:  
›ï
‡Øú‡Øù‡Øû‡Øü= ﬂ§‡¨¥+  ﬂö‡¨µ›è›ä›Å‹Æ‡Øú‡Øù‡Øû+ ﬂö‡¨∂›Ä›ã›Ö›é›Å‹≤ ‡Øù+ ﬂö‡¨∑›Å‹ø›ä›Å›ë›ç›Å‹µ ‡Øû + ﬂù‡Øú‡Øù‡Øû‡Øü 
 
x ﬂ§‡¨¥: overall intercept; 
x ›è›ä›Å‹Æ‡Øú‡Øù‡Øû: Lens indicator; ›è›ä›Å‹Æ‡Øú‡Øù‡Øû=[ADDRESS_985626] and 0 otherwise;  
x ›Ä›ã›Ö›é›Å‹≤ ‡Øù  : effect of the ›Üth period; period=1 if analysis period=1 and 0 otherwise 
x ﬂù‡Øù‡Øû‡Øü: random error associated with the ›Üth period for the lth subject for the ith 
treatment assigned to the kth lens sequence   
x ·âÇﬂù‡¨µ‡Øû‡Øü
ﬂù‡¨∂‡Øû‡Øü·âÉ‹∞·âÜ·âÇ
·âÉ·âàﬂ™‡¨µ‡¨µ‡¨∂ﬂ™‡¨µ‡¨∂
ﬂ™‡¨∂‡¨µﬂ™‡¨∂‡¨∂‡¨∂·ââ·âá
 
  
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Hypothesis Testing 
The null and alternative hypotheses for the signifi cance testing between the Test lens and the 
Control lens with respects to each chromaticity coordinate for color appearance are presented 
below: 
 
‹™‡Øàﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü 
‹™‡Æ∫ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü‡µç 
where ﬂ§‡Øç‡Øò‡Ø¶‡Øß‡µÜﬂ§‡Æº‡Ø¢‡Ø°‡Øß‡Ø•‡Ø¢‡Øü  the population mean difference be tween the Test and the Control 
lenses. Statistical differences will be concluded if 0 is not contained within the 95% confidence interval. 
14.8. Interim Analysis 
Not applicable. 
14.9. Procedure for Handling Missing Data and Drop-Outs 
Missing or spurious values will not be imputed. The count of mi ssing values will be included 
in the summary tables and listings.   Subject dropout is expected to be one of the main reasons of missing data in this clinical trial. 
Past clinical trials don‚Äôt provide the evidence that subject dropout is systematic or not-at-random. To evaluate the impact of missing data , sensitivity analysis will be conducted using 
multiple imputation methods if the proportion of subject dropout is greater than the 15%. The 
SAS/STAT procedures PROC MI and PROC MI ANALYZE will be utilized with a parametric 
regression method used to ma ke at least [ADDRESS_985627] KEEPI[INVESTIGATOR_1645]/ARCHIVING 
15.1. Electronic Case Report Form/Data Collection 
The data for this study will be captured on el ectronic case report forms (eCRFs) using the 
BioClinica EDC system. An authorized data or iginator will enter study data into the eCRFs 
using the EDC system. Data collected on equipm ent that is not captured in EDC will be 
formatted to the specification of the JJVC databa se manager and sent to JJVC for analysis.  
 
External data sources for this study include:  Not applicable. 
 The clinical data will be recorded on dedicated eCRFs specifically designed to match the study procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_941] 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Investigator. The sponsor or sponsor‚Äôs representa tives will be authorized to gain access to the 
subject recordation for the purposes of  monitoring and auditing the study.  
 
Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and complete data collection. Data w ill be transmitted from the clinical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with Individual Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of the study data. The IPP must be retained in the study files as a certified copy of the source data 
for the study.   The content and structure of the eCRFs are compliant with ISO14155:2020.
[ADDRESS_985628] should be available for the following:  
x subject identification 
x eligibility 
x study identification 
x study discussion 
x provision of and date of informed consent 
x visit dates 
x results of safety and efficacy para meters as required by [CONTACT_760] 
x a record of all adverse events 
x follow-up of adverse events 
x medical history and concomitant medication 
x test article receipt/dispensing/return records 
x date of study completion 
x reason for early discontinuation of test article or withdrawal from the study, if applicable  
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of  entry is considered to be the source record. 
 Adverse event notes must be reviewed and initialed by [CONTACT_737].  
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov based on the following: The study is determined not to be an early feasibility study.  
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
16. DATA MANAGEMENT 
16.1. Access to Source Data/Document 
The Investigator/Institution will permit trial-rela ted monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_20618]/documents. Should the 
clinical site be contact[CONTACT_35527]/IRB or regulatory authority, JJVC must be 
contact[CONTACT_35528] [ADDRESS_985629] a nd therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands  that he/she has an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor. 
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of data, include the selection of 
qualified investigators and appropriate clinical sites and revi ew of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site  personnel are familiar with the protocol and all study-specific 
procedures and have appropriate  knowledge of the study article. 
 Training on case report form comp letion will be provided to clinic al site personnel before the 
start of the study. The Sponsor will review case  report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be resolved with the Investigator or designee, as appropriate.  Quality Assurance representatives from JJVC may visit clinical sites to review data produced during the study and to access compliance with applicable regulations pertaining to the conduct of clinical trials. The clinical sites will provide direct access to study-related source data/documents and reports for the purpose of monitoring and auditing by [CONTACT_35529]. 
16.4. Data Monitoring Committee (DMC) 
Not applicable 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
17. CLINICAL MONITORING 
The study monitors will maintain close contact  [CONTACT_35530] [INVESTIGATOR_35453]‚Äôs designated clinical site personnel. The monitor‚Äôs responsibilities will include: 
x Ensuring that the investigation is being conducted according to the protocol, any 
subsequent versions, and regulat ory requirements are maintained. 
x Ensuring the rights and wellbei ng of subjects are protected. 
x Ensuring adequate resources, including fac ilities, laboratories, equipment, and 
qualified clinical site personnel. 
x Ensuring that protocol deviations are doc umented with corrective action plans, as 
applicable. 
x Ensuring that the clinical site has sufficient test article and supplies. 
x Clarifying questions regarding the study. 
x Resolving study issues or problems that may arise. 
x Reviewing of study records and source documentation verification in accordance with 
the monitoring plan. 
18. ETHICAL AND REGULATORY ASPECTS 
18.1. Study-Specific Design Considerations 
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new informati on that may affect their decision to continue 
participation. Subjects will be told that their consent to participate in the study is voluntary and 
may be withdrawn at any time with  no reason given and without pena lty or loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if the subject is / fully able to understand the risks, be nefits, and potential adverse events of the study and provide  
their consent voluntarily. 
18.2. Investigator Responsibility 
The Principal Investigator [INVESTIGATOR_35454], the investigational plan, Section 4 of the ICH E6(R2) guidelines on Good Clinical Practice (GCP),
[ADDRESS_985630] maintain 
clinical study files in accordance with Section 8 of the ICH E6(R2) guidelines on Good Clinical 
Practice (GCP),[ADDRESS_985631] (IEC/IRB) 
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copi[INVESTIGATOR_35455] (where applicable): 
x Final protocol. 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
x Sponsor-approved informed consent form (a nd any other written materials to be 
provided to the subjects) 
x Investigator‚Äôs Brochure (o r equivalent information). 
x Sponsor-approved subject r ecruitment materials. 
x Information on compensation for study-relate d injuries or payment to subjects for 
participation in the study. 
x Investigator‚Äôs curriculum vitae, clinical li censes, or equivalent information (unless not 
required, as documented by [CONTACT_8134]/IRB). 
x Information regarding funding, name [CONTACT_35596] e Sponsor, institutiona l affiliations, other 
potential conflicts of interest, and incentives for subjects. 
x Any other documents that the IEC/IRB requests to fulfill its obligation. 
 
This study will be undertaken only after IEC/IRB has given full approval of  the final protocol, 
the informed consent form, applicable recruiting materials, and subject compensation programs, and the Sponsor has received a copy of  this approval. This approval letter must be 
dated and must clearly identify the documents being approved. 
 During the study, the Investigator (or Sponsor  when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate: 
x Protocol revisions 
x Revision(s) to informed consent form and any other written materials to be provided to subjects 
x If applicable, new or revise d subject recruitment materi als approved by [CONTACT_1034] 
x Revisions to compensation for study-related injuries or payment to subjects for participation in the study 
x Investigator‚Äôs Brochure revisions  
x Summaries of the status of the study (at leas t annually or at intervals stipulated in 
guidelines of the IEC/IRB) 
x Reports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRB‚Äôs requirements 
x New information that may adversely affect th e safety of the subjects or the conduct of 
the study 
x Major protocol deviations as required by [CONTACT_6179]/IRB 
x Report of deaths of subjects under the Investigator's care 
x Notification if a new Investigator is res ponsible for the study at the clinical site 
x Any other requirements of the IEC/IRB 
 For protocol revisions that incr ease subject risk, the revisions and applicable informed consent 
form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s).  At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.  
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this no tification must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable. 
18.4. Informed Consent 
Each subject or their representative, must give written consent according to local requirements after the nature of the study has been fully explained. The consent form must be signed before performance of any study-related activity. The cons ent form that is used must be approved by 
[CONTACT_19597]/IRB. Th e informed consent is in accordance with 
principles that originated in the Declaration of Helsinki,
3 current ICH GCP2 and ISO 
[ZIP_CODE]:[ADDRESS_985632]'s dated signature. After having obtained the 
consent, a copy of the informed consen t form must be given to the subject. 
18.5. Privacy of Personal Data 
The collection, processing and disclosure of pers onal data and medical information related to 
the Study Subject, and personal data  related to Principal Investig ator and any clinical site 
personnel (e.g., name, clinic addr ess and phone number, curriculum vitae) is subject to 
compliance with the Health Information Portability and Accountability Act (HIPAA)
[ADDRESS_985633] these data, to maintain the confidentiality of the person‚Äôs related health and me dical information, to properly inform the concerned persons 
about the collection and processing of their pers onal data, to grant them reasonable access to 
their personal data and to preven t access by [CONTACT_35532]. 
 All information obtained during the course of the investigation will be regarded as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by [CONTACT_4718], monitors, Sponsor‚Äôs personnel and IEC/IRB. No data will be disclose d to any third party 
without the express permission of the subject  concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulat ory organizations in the context of their 
investigation related activities that, as part of the investigation will have access to the CRFs and subject records.  The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to investigate the efficacy, safety, quality, and utility of the investigational product( s) used in this study. 
	0 
!&$
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data pr ivacy protection laws and regulations. 
The Sponsor ensures that the personal data will be: 
x processed fairly and lawfully. 
x collected for specified, explicit, and legitimate purposes and not further processed in a way incompatible with these purposes. 
x adequate, relevant, and not excessive in relation to said purposes. 
x accurate and, where necessary, kept current. 
 Explicit consent for the processing of personal data will be obtained from the participating subject before collection of data . Such consent should also addre ss the transfer of the data to 
other entities and to other countries.  The subject has the right to request through the Investigator access to hi s personal data and the 
right to request rectification of  any data that are not correct or complete. Reasonable steps 
should be taken to respond to such  a request, taking into considera tion the nature of the request, 
the conditions of the study, and the applicable laws and regulations. 
 Appropriate technical and orga nizational measures to protec t the personal data against 
unauthorized disclosures or acces s, accidental or unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor pe rsonnel whose responsibilities require access to 
personal data agree to keep the id entity of study subjects confidential. 
19. STUDY RECORD RETENTION 
In compliance with the ICH GCP guidelines,
2 the Investigator/Institution will maintain all 
CRFs and all subject records that support the data  collected from each subject, as well as all 
study documents as specified in ICH GCP2 and all study documents as specified by [CONTACT_12926](s). The Investigator/Institution will take measures to prevent accidental or premature destruction of these documents.  Essential documents must be retained until at least two (2) years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least two (2) years have elapsed since the formal discontinuation of clin ical development of the i nvestigational product. These 
documents will be retained for a longer peri od if required by [CONTACT_35533]. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained. 
 If the responsible Investigator retires, relocat es, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will accept the responsibility. The Sponsor must be notified in writing of the name [CONTACT_19619]. Under no circumstance shall the Investigator relocate or dispose of any study documents before having obtaine d written approval from the Sponsor. 
 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
If it becomes necessary for the Sponsor or the ap propriate regulatory auth ority to review any 
documentation relating to this study, the Investig ator must permit access to such reports.  
If the Investigator has a question regarding rete ntion of study records, he/she should contact 
[CONTACT_19599].  
20. FINANCIAL CONSIDERATIONS 
Remuneration for study services and expenses will be set forth in de tail in the Clinical Research 
Agreement. The Research Agreement will be signed by [CONTACT_079] [INVESTIGATOR_1238] a JJVC 
management representativ e prior to study initiation. 
 JJVC reserves the right to withhold remuneration fo r costs associated with protocol violations 
such as: 
x Continuing an ineligible subject in the study. 
x Scheduling a study visit outside the subject‚Äôs acceptable visit range. 
 
JJVC reserves the right to withhold final rem uneration until all study related activ ities have 
been completed, such as: 
x Query resolution. 
x Case Report Form signature. 
x Completion of any follow-up action items. 
21. PUBLICATION 
There is no plan to publish this outcome of this investigation. 
22. REFERENCES 
1. 
ISO [ZIP_CODE]:2011: Clinical Investigation of Medical Devices for Human Subjects ‚Äî Good 
Clinical Practice. Available at: https://www.iso.org/standard/[ZIP_CODE].html  
2. International Conference on Harmonization Good Clinical Practice E6 (ICH-GCP). Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html  
3. Declaration of Helsinki - Ethical principles for Medical Research Involving Human Subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/  
4. [LOCATION_002] (US) Code of Federa l Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collect ionCfr.action?collectionCode=CFR  
5. Health Information Portability and Accountability Act (HIPAA). Available at: 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html    
6. SAS Institute Inc. 2016 SAS/STAT¬Æ 14.3 User‚Äôs Guide. Cary, NC: SAS Institute Inc.  
7. Keselman HJ, Algina J, Kowalchuk RK, Wolfi nger RD. A comparison of two approaches for 
selecting covariance structures in the analysis of repeated measurements. Communications in 
Statistics - Simulation and Computation. 1998;27(3):591-604. 
8. Kenward MG, Roger JH. Small Sample Inference for Fixed Effects from Restricted 
Maximum Likelihood. Biometrics. 1997;53(3):983. 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
9. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on 
medical devices. Available at:  
http://data.europa.eu/eli/reg/2017/745/2017-05-05 
 
  
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) 
Not Applicable. 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX B: PATIENT INSTRUCTION GUIDE   
A Patient Instruction Guide (PIG) will be provided separately. 
 
	0 
!&$+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) 
  
	0 
!&$	+%	
 
IMPORTANT: Please read carefully and keep this 
information for future use.
This Package Insert and Fitting Guide is intended 
for the Eye Care Professional, but should be made 
available to patients upon request. The Eye Care 
Professional should provide the patient with the 
patient instructions that pertain to the patient‚Äôs 
prescribed lenses.
ACUVUE¬Æ OASYS MULTIFOCAL (senofilcon A) Contact [CONTACT_721549] (hydrophilic) Contact [CONTACT_721550] & Extended Wear 
CAUTION: US Federal law restricts this device to sale 
by [CONTACT_35537] a licensed practitionerACUVUE¬Æ OASYS MULTIFOCAL Contact [CONTACT_721551] & FITTING INSTRUCTION GUIDE
	0 
!&$
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
‚Ä¢ Light Transmittance: ‚â•89% minimum
‚Ä¢ Surface Character: Hydrophilic‚Ä¢ Water Content: 38%‚Ä¢ Oxygen Permeability (Dk):
VALUE METHOD
103 x 10-11 (cm2/sec) (ml 
O2/ml x mm Hg) at 35¬∞CFatt (boundary corrected, edgse 
corrected)
122 x 10-11 (cm2/sec) (ml 
O2/ml x mm Hg) at 35¬∞CFatt (boundary corrected, non- edge corrected)
Lens Parameters Ranges:
The ACUVUE¬Æ OASYS MULTIFOCAL (senofilcon A) Soft 
Contact [CONTACT_721552]:
‚Ä¢ Diameter (DIA) : 12.0 mm to 15.0 mm
‚Ä¢ Center Thickness: varies with power
‚Ä¢ Base Curve (BC): 7.85 mm to 10.00 mm
‚Ä¢ Spherical Power (D): -20.00D to [PHONE_565]D
‚Ä¢ Multifocal ADD Power Range: +0.25D to +4.00D
Each lens is supplied in a foil-sealed plastic package containing borate buffered saline solution with methyl ether cellulose.
AVAILABLE LENS PARAMETERS
The ACUVUE¬Æ OASYS MULTIFOCAL (senofilcon A) Soft 
Contact [CONTACT_721553]:
Diameter: 14.3 mm
Center Thickness: Minus Lens - varies with power (e.g. -4.00D: 0.070 mm)Plus Lens - varies with power (e.g. +4.00D: 0.168
	0 
!&$
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Base Curve: 8.4 mm
Powers: -9.00D to +6.00D (in 0.25D increments)
ADD Powers: +1.25 (LOW), +1.75 (MID), +2.50 (HGH)
 
TRANSMITTANCE CURVE
ACUVUE¬Æ OASYS MULTIFOCAL (senofilcon A) Soft Contact 
[CONTACT_721554]. 24 yr. old human cornea vs. 25 yr. old human 
crystalline lens.
‚Ä¶‚Ä¶. ACUVUE¬Æ OASYS 
MULTIFOCAL 
(senofilcon A) Contact [CONTACT_32993]*
_____ 24 YR OLD HUMAN CORNEA
1
- - - - - 25 YR OLD HUMAN CRYSTALLINE LENS
2
 
*The data was obtained from measurements taken through the central 3-[ADDRESS_985634] marketed lens (-1.00D lens, 0.070 mm center thickness).
1 Lerman, S., Radiant Energy and the Eye, MacMillan, New 
York, 1980, p.58, figure 2-21.
2 Waxler, M. Hitchins, V.M., Optical Radiation and Visual Health, 
CRC Press, Boca Raton, [LOCATION_012], 1986, p.19, figure 5.
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
ACTIONS
In its hydrated state, the contact [CONTACT_13293], when placed on the 
cornea, acts as a refracting medium to focus light rays on the retina.
When hydrated and placed on the cornea for therapeutic use, 
the contact [CONTACT_721555] a bandage to protect the cornea.
These lenses contain a UV Blocker to help protect against 
transmission of harmful UV radiation to the cornea and into the eye.  The light transmittance characteristics are less than 1% in the UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 315 nm to 380 nm for the entire power range.
WARNING: UV absorbing contact [CONTACT_721556], such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. The patient should continue to use UV absorbing eyewear as directed.
Note: Long-term exposure to UV radiation is one of the 
risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV Blocking contact [CONTACT_35540]. However, clinical studies have not been done to demonstrate that wearing UV Blocking contact [CONTACT_35541][INVESTIGATOR_35457]. The Eye Care Professional should be consulted for more information.
INDICATIONS (USES)
ACUVUE¬Æ OASYS MULTIFOCAL (senofilcon A) Contact [CONTACT_721557]-diseased eyes who ither presby[CONTACT_721558] 
	0 	
	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
presby[CONTACT_721559] (myopic) or farsighted 
(hyperopic) and may have 0.75D or less of astigmatism. 
Eye Care Professionals may prescribe the lenses either for 
single use, disposable wear or frequent/planned replacement wear with cleaning, disinfection and scheduled replacement (see ‚ÄúReplacement Schedule‚Äù). When prescribed for single use disposable wear, no cleaning or disinfection is required. Lenses should be discarded upon removal. When prescribed for frequent/planned replacement wear, the lenses may be disinfected using a chemical disinfection system only. 
These lenses are intended for daily wear for up to 14 days 
(2 weeks) and extended wear for up to 6 nights/[ADDRESS_985635] be evaluated on a daily wear schedule. If successful, then a gradual introduction of extended wear can be followed as determined by [CONTACT_71187]. 
These lenses are also indicated for therapeutic use as a 
bandage lens for the following acute and chronic ocular conditions:
‚Ä¢ For corneal protection in lid and corneal abnormalities 
such as entropi[INVESTIGATOR_2394], trichiasis, tarsal scars, and recurrent corneal erosion. In addition, they are indicated for protection where sutures or ocular structure malformation, degeneration or paralysis may result in the need to protect the cornea from exposure or repeated irritation.
‚Ä¢ For corneal pain relief in conditions such as bullous 
keratopathy, epi[INVESTIGATOR_721520], Ô¨Ålamentary keratitis, and post-keratoplasty.
‚Ä¢ For use as a barrier during the healing process of epi[INVESTIGATOR_721521], corneal ulcer, neurotrophic and neuroparalytic keratitis, and chemical burns.
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
‚Ä¢ For post-surgical conditions where bandage lens use is 
indicated such as post refractive surgery, lamellar grafts, 
corneal Ô¨Çaps, and additional ocular surgical conditions.
‚Ä¢ For structural stability and protection in pi[INVESTIGATOR_721522] 
Ô¨Åtting where the cornea and associated surfaces are too irregular to allow for corneal rigid gas permeable (RGP) lenses to be Ô¨Åt. In addition, the use of the lens can prevent irritation and abrasions in conditions where there are elevation differences in the host/graph junction or scar tissue.
Lenses prescribed for therapeutic use may be worn for daily or extended wearing periods.
CONTRAINDICATIONS (REASONS NOT TO USE)
When prescribing contact [CONTACT_721560], DO NOT USE these lenses when any of the following conditions exist:
‚Ä¢ Acute or subacute inflammation or infection of the anterior 
chamber of the eye.
‚Ä¢ Any eye disease, injury or abnormality that affects the 
cornea, conjunctiva or eyelids.
‚Ä¢ Severe insufficiency of lacrimal secretion (dry eye).
‚Ä¢ Corneal hypoesthesia (reduced corneal sensitivity).‚Ä¢ Any systemic disease that may affect the eye or be 
exaggerated by [CONTACT_35543].
‚Ä¢ Allergic reactions of ocular surfaces or adnexa that may be 
induced or exaggerated by [CONTACT_721561].
‚Ä¢ Ocular irritation due to allergic reactions which may be 
caused by [CONTACT_35545] (i.e., cleaning and disinfecting solutions, rewetting drops, etc.) that contain chemicals or preservatives (such as mercury, Thimerosal, 
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
etc.) to which some people may develop an allergic 
response.
‚Ä¢ Any active corneal infection (bacterial, fungal, protozoal 
or viral).
‚Ä¢ If eyes become red or irritated.
For THERAPEUTIC USE, the Eye Care Professional may prescribe these lenses to aid in the healing process of certain ocular conditions, which may include those cited above.
WARNINGS
Patients should be advised of the following warnings pertaining to contact [CONTACT_13279]: 
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN 
DEVELOP RAPI[INVESTIGATOR_35458]. IF THE PATIENT EXPERIENCES:
‚Ä¢ Eye Discomfort,
‚Ä¢ Excessive Tearing,‚Ä¢ Vision Changes,‚Ä¢ Loss of Vision,‚Ä¢ Eye Redness, or‚Ä¢ Other Eye Problems,
THE PATIENT SHOULD BE INSTRUCTED TO 
IMMEDIATELY REMOVE THE LENSES AND PROMPTLY CONTACT [CONTACT_35546].
‚Ä¢ When prescribed for daily wear, patients should be 
instructed not to wear their lenses while sleepi[INVESTIGATOR_007]. Clinical studies have shown that when lenses are worn overnight, the risk of ulcerative keratitis is greater than among those who do not wear them overnight.
3
‚Ä¢ Studies have shown that contact [CONTACT_288815] a higher incidence of adverse reactions than nonsmokers.
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
‚Ä¢ Problems with contact [CONTACT_721562]. Patients should be 
cautioned that proper use and care of contact [CONTACT_154143], including lens cases, are essential for the safe use of these products.
‚Ä¢ The overall risk of ulcerative keratitis may be reduced 
by [CONTACT_253446], including cleaning the lens case.
3 New England Journal of Medicine, September 21, 1989; 321 
(12), pp. 773-783
Specific Instructions for Use and Warnings:
‚Ä¢ Water Activity
Instruction for Use
Do not expose contact [CONTACT_35551]. WARNING:Water can harbor microorganisms that can lead to 
severe infection, vision loss, or blindness. If lenses have been submersed in water when participating in water sports or swimming in pools, hot tubs, lakes or oceans, the patient should be instructed to discard them and replace them with a new pair. The Eye Care Professional should be consulted for recommendations regarding wearing lenses during any activity involving water.
‚Ä¢ Soaking and Storing Your Lenses
Instruction for Use
Use only fresh multi-purpose (contact [CONTACT_721563]) 
solution each time the lenses are soaked (stored).
WARNING:
Do not reuse or ‚Äútop off‚Äù old solution left in the lens 
case since solution reuse reduces effective lens disinfection and could lead to severe infection, vision loss, or blindness.  
	0 
!&$	+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
‚ÄúToppi[INVESTIGATOR_007]-Off‚Äù is the addition of fresh solution to 
solution that has been sitting in the case.
‚Ä¢ Discard Date on Multi-Purpose Solution Bottle
Instructions for Use
‚Äì Discard any remaining solution after the recommended 
time period indicated on the bottle of multi-purpose 
solution used for disinfecting and soaking the contact [CONTACT_13276].
‚Äì The discard date refers to the time that the patient can 
safely use the contact [CONTACT_721564]. It is not the same as the expi[INVESTIGATOR_320], which is the last date that the product is still effective before it is opened. 
WARNING:
Using multi-purpose solution beyond the discard date 
could result in contamination of the solution and can lead to severe infection, vision loss, or blindness.
‚Äì To avoid contamination, DO NOT touch tip of 
container to any surface. Replace cap after using.
‚Äì To avoid contaminating the solution, DO NOT 
transfer to other bottles or containers.
‚Ä¢ Rub and Rinse Time
Instruction for UseTo adequately disinfect the lenses, the patient should rub and 
rinse the lenses according to the recommended lens rubbing and rinsing times in the labeling of the multi-purpose solution. WARNING:
‚Äì Rub and rinse lenses for the recommended amount 
of time to help prevent serious eye infections.
‚Äì Never use water, saline solution, or rewetting drops 
to disinfect the lenses. These solutions will not 
disinfect the lenses. Not using the recommended 
	0 
!&$
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
disinfectant can lead to severe infection, vision loss, 
or blindness.
‚Ä¢ Lens Case Care
Instructions for Use
‚Äì Empty and clean contact [CONTACT_721565], sterile disinfecting solutions/contact [CONTACT_721566]. Never use water. Cleaning should be followed by [CONTACT_721567], sterile disinfecting solutions (never use water) and wipi[INVESTIGATOR_721523], clean tissue is recommended. Never air-dry or recap the lens case lids after use without any additional cleaning methods. If air drying, be sure that no residual solution remains in the case before allowing it to air-dry.
‚Äì Replace the lens case according to the directions provided 
by [CONTACT_721568]‚Äôs labeling that accompanies the case. 
‚Äì Contact [CONTACT_93899] a source of bacterial growth.
WARNING:
Do not store lenses or rinse lens cases with water 
or any non-sterile solution. Only fresh multi-purpose solution should be used to prevent contamination of the lenses or lens case. Use of non-sterile solution can lead to severe infection, vision loss, or blindness.
PRECAUTIONS
Special Precautions for Eye Care Professionals:
‚Ä¢ Due to the small number of patients enrolled in clinical 
investigation of lenses, all refractive powers, design configurations or lens parameters available in the lens material are not evaluated in significant numbers. Consequently, when selecting an appropriate lens design and parameters, the Eye Care Professional should consider all characteristics of the lens that can affect 
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
lens performance and ocular health, including oxygen 
permeability, wettability, central and peripheral thickness and optic zone diameter.
The potential impact of these factors on the patient's 
ocular health should be carefully weighed against the patient's need for refractive correction; therefore, the continuing ocular health of the patient and lens performance on the eye should be carefully monitored by [CONTACT_71187].
‚Ä¢ Patients who wear these lenses to correct presby[CONTACT_721569]. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient. 
‚Ä¢ Eye Care Professionals should instruct the patient to 
remove lenses immediately if the eyes become red or irritated.
‚Ä¢ Eye Care Professionals should instruct the patient to 
always have a functional pair of spectacles with a current prescription available to use if the patient becomes unable to wear contact [CONTACT_13276], or in circumstances where contact [CONTACT_721570].
Eye Care Professionals should carefully instruct patients about the following care regimen and safety precautions:
Handling Precautions:
‚Ä¢ DO NOT use if the sterile blister package is opened or 
damaged. 
‚Ä¢ Always wash, rinse, and dry hands before handling lenses. 
It is best to put on lenses before putting on makeup. 
‚Ä¢ Carefully follow the handling, insertion, removal, cleaning, 
disinfecting, storing and wearing instructions in the Patient 
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Instruction Guide for these lenses and those prescribed by 
[CONTACT_35578].
‚Ä¢ Never use tweezers or other tools to remove lenses from 
the lens container. Slide the lens up the side of the bowl until it is free of the container.
‚Ä¢ Close supervision is necessary for the Therapeutic use of 
these lenses. Ocular medications used during treatment with a bandage lens should be closely monitored by [CONTACT_35578]. In certain ocular conditions, only the Eye Care Professional will insert and remove the lenses. In these cases, patients should be instructed not to handle the lenses themselves.
Lens Wearing Precautions:
‚Ä¢ If the lens sticks (stops moving) on the eye, follow the 
recommended directions in "Care for Sticking (Non-Moving) Lenses". The lens should move freely on the eye for the continued health of the eye. If non-movement of the lens continues, the patient should be instructed to immediately consult his or her Eye Care Professional.
‚Ä¢ Never wear lenses beyond the period recommended by 
[CONTACT_35578].
‚Ä¢ The patient should be advised to never allow anyone else 
to wear their lenses. Sharing lenses greatly increases the chance of eye infections.
‚Ä¢ If aerosol products, such as hair spray, are used while 
wearing lenses, exercise caution and keep eyes closed until the spray has settled.
‚Ä¢ Avoid all harmful or irritating vapors and fumes while 
wearing lenses. 
‚Ä¢ The patient should be advised to never rinse the lenses 
in water from the tap. Tap water contains many impurities that can contaminate or damage the lenses and may lead to eye infection or injury.
	0 
!&$
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Lens Care Precautions:
‚Ä¢ Different solutions cannot always be used together and 
not all solutions are safe for use with all lenses. Use only 
recommended solutions.
‚Ä¢ Do not change solution without consulting with the Eye 
Care Professional. 
‚Ä¢ Never use solutions recommended for conventional hard 
contact [CONTACT_653804].
‚Ä¢ Always use fresh, unexpi[INVESTIGATOR_721524], and always follow directions in the package inserts for the use of contact [CONTACT_93897].
‚Ä¢ Sterile unpreserved solutions, when used, should be 
discarded after the time specified in the directions. 
‚Ä¢ Do not use saliva or anything other than the 
recommended solutions for lubricating or wetting lenses. 
‚Ä¢ Always keep the lenses completely immersed in the 
recommended storage solution when the lenses are not being worn (stored). Prolonged periods of drying (e.g., exposing the lens to air for 30 minutes or more) will reduce the ability of the lens surface to return to a wettable state. If the lens surface does become dried out, discard the lens and use a new one.
Other Topi[INVESTIGATOR_35460]:
‚Ä¢ Always contact [CONTACT_721571]. 
‚Ä¢ Certain medications, such as antihistamines, 
decongestants, diuretics, muscle relaxants, tranquilizers, and those for motion sickness may cause dryness of the eye, increased lens awareness or blurred vision. Should such conditions exist, proper remedial measures should be prescribed. 
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
‚Ä¢ Oral contraceptive users could develop visual changes 
or changes in lens tolerance when using contact [CONTACT_13276]. 
Patients should be cautioned accordingly. 
‚Ä¢ Do not change lens type (e.g. brand name, etc.) or 
parameters (e.g. diameter, base curve, lens power, etc.) without consulting the Eye Care Professional. 
‚Ä¢ Instruct patients to always confirm the lens parameters 
printed on the multi-pack and on the individual lens package match their prescription. If there is a mismatch the patient should not use the product.
‚Ä¢ As with any contact [CONTACT_13293], follow-up visits are necessary 
to assure the continuing health of the patient's eyes. The patient should be instructed as to a recommended follow-up schedule.
Who Should Know That the Patient is Wearing Contact [CONTACT_32993]?
‚Ä¢ Patients should inform all doctors (Health Care 
Professionals) about being a contact [CONTACT_35560]. 
‚Ä¢ Patients should always inform their employer of being a 
contact [CONTACT_35560]. Some jobs may require use of eye protection equipment or may require that the patient not wear contact [CONTACT_13276].
ADVERSE REACTIONS
The patient should be informed that the following problems may occur when wearing contact [CONTACT_13276]:
‚Ä¢ The eye may burn, sting and/or itch.
‚Ä¢ There may be less comfort than when the lens was first 
placed on the eye.
‚Ä¢ There may be a feeling of something in the eye (foreign 
body, scratched area).
‚Ä¢ There may be the potential for some temporary 
impairment due to peripheral infiltrates, peripheral 
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
identification of the problem and prompt treatment to avoid 
serious eye damage.
GENERAL FITTING GUIDELINES
A. Patient Selection
Patients selected to wear these lenses should be chosen based on:
‚Ä¢ Motivation to wear lenses
‚Ä¢ Ability to follow instructions regarding lens wear care‚Ä¢ General health‚Ä¢ Ability to adequately handle and care for the lenses‚Ä¢ Ability to understand the risk and benefits of lens wear
Patients who do not meet the above criteria should not be 
provided with contact [CONTACT_13276].
B. Pre-fitting Examination
Initial evaluation of the patient should begin with a thorough case history to determine if there are any contraindications to contact [CONTACT_13279]. During the case history, the patient‚Äôs visual needs and expectations should be determined as well as an assessment of their overall ocular, physical, and mental health. 
Preceding the initial selection of trial contact [CONTACT_13276], a 
comprehensive ocular evaluation should be performed that includes, but is not limited to, the measurement of distance and near visual acuity, distance and near refractive prescription (including determining the preferred reading distance for presby[CONTACT_35562]), keratometry and biomicroscopic evaluation. 
Based on this evaluation, if it is determined that the patient 
is eligible to wear these lenses, the Eye Care Professional should proceed to the appropriate lens fitting instruction outlined below.
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
C. Initial Power Determination
A spectacle refraction should be performed to establish 
the patient‚Äôs baseline refractive status and to guide in the selection of the appropriate lens power. Remember to compensate for vertex distance if the refraction is greater than ¬±4.00D.
D. Base Curve Selection (Trial Lens Fitting)
The following trial lenses should be selected for the patient regardless of keratometry readings. However, corneal curvature measurements should be performed to establish the patient‚Äôs baseline ocular status.
‚Ä¢ ACUVUE
¬Æ OASYS MULTIFOCAL (senofilcon A) Soft 
Contact [CONTACT_19550]: 8.4 mm/14.3 mm
The trial lenses should be placed on each of the patient‚Äôs eyes and evaluated after the patient has adjusted to the lenses.
1. Criteria of a Properly Fit Lens
A properly fit lens will center and completely cover the 
cornea (i.e., no limbal exposure), have sufficient movement to provide tear exchange under the contact [CONTACT_35563], and be comfortable. The lens should move freely when manipulated digitally with the lower lid, and then return to its properly centered position when released. 
2. Criteria of a Flat Fitting Lens
A flat fitting lens may exhibit one or more of the following 
characteristics: decentration, incomplete corneal coverage (i.e., limbal exposure), excessive movement with the blink and/or edge standoff. If the lens is judged to be flat fitting, it should not be dispensed to the patient.
3. Criteria of a Steep Fitting Lens
A steep fitting lens may exhibit one or more of the following 
characteristics: insufficient movement with the blink, conjunctival indentation, and resistance when pushing the 
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
lens up digitally with the lower lid. If the lens is judged to be 
steep fitting, it should not be dispensed to the patient.
If the initial trial base curve is judged to be flat or steep fitting, the alternate base curve, if available, should be trial fit and evaluated after the patient has adjusted to the lens. The lens should move freely when manipulated digitally with the lower lid, and then return to a properly centered position when released. 
All patients should be supplied with a copy of the 
PATIENT INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35461].acuvue.com.
MULTIFOCAL FITTING GUIDELINES
A. Presby[CONTACT_253453] & Patient Education
Multifocal contact [CONTACT_721572] (i.e., reading a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). Therefore, caution should be exercised when the patient is wearing the correction for the first time until they are familiar with the vision provided in visually challenging environments. Occupational and environmental visual demands should be considered. If the patient requires critical visual acuity and stereopsis, it should be determined by [CONTACT_253455]
¬Æ OASYS MULTIFOCAL (senofilcon A) Soft Contact 
[CONTACT_19550]. Wear may not be optimal for such activities as:
1. Visually demanding situations such as operating potentially 
dangerous machinery or performing other potentially hazardous activities; and
2. Driving automobiles (e.g., driving at night). Patients who 
cannot pass their state driver‚Äôs license requirements with these lenses should be advised to not drive with this 
	0 
!&$	+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
correction, OR may require that additional over-correction 
be prescribed.
These lenses are not recommended for patients who have ‚Äì1.00D or greater of refractive cylinder as this level of uncorrected cylinder may lead to additional visual compromise. 
These lenses are available in the following ADD powers:
‚Ä¢ Lens ‚ÄúLOW‚Äù =‚Äúlow‚Äù near ADD lens (Max +1.25 ADD)
‚Ä¢ Lens ‚ÄúMID‚Äù = ‚Äúmedium‚Äù near ADD lens (Max +1.75 ADD)‚Ä¢ Lens ‚ÄúHGH‚Äù = ‚Äúhigh‚Äù near ADD lens (Max +2.50 ADD)
B. Initial Power Determination 
A spectacle refraction should be performed to establish the 
patient‚Äôs baseline refractive status and to guide in the selection of the appropriate lens power. Remember to compensate for vertex distance if the refraction is greater than ¬±4.00D. Determine the spherical equivalent distance prescription for a multifocal patient. Determine the eye dominance using one of the methods below:
 Method 1: Determine which eye is the ‚Äúsighting eye.‚Äù Have the patient point to an object at the far end of the room. Cover one eye. If the patient is still pointing directly at the object, the eye being used is the dominant (sighting) eye.
Method 2 (preferred): Determine which eye will not accept 
added power. Place a +1.[ADDRESS_985636] to the patient‚Äôs distance spherical equivalent. 
	0 
!&$
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Remember to compensate for vertex distance if the 
refraction is greater than ¬±4.00D.
2. Select the near power of the lens based on the patients 
ADD range as follows: 
‚Ä¢ ADD: +0.75 to +1.25 use a ‚ÄúLOW‚Äù near ADD lens on 
each eye 
‚Ä¢ ADD: +1.50 to +1.75 use a ‚ÄúMID‚Äù near ADD lens on 
each eye
‚Ä¢ ADD: +2.00 to +2.50 use a ‚ÄúMID‚Äù near ADD on the 
dominant eye and a ‚ÄúHGH‚Äù near ADD lens on the non-
dominant eye
3. Allow the lenses to settle for a minimum 10 minutes.
4. Assess distance and near vision binocularly and 
monocularly.
5. Demonstrate the vision under various lighting conditions 
(normal and decreased illumination) and at distance, 
intermediate and near. 
6. Make adjustments in power as necessary based on the 
distance over-refraction.  The use of hand held trial lenses is recommended.  Check the impact on distance and near vision.
7. If vision is still unacceptable, make adjustments in power 
as necessary (see ‚ÄúMultifocal Troubleshooting‚Äù  
below). If distance and near vision are acceptable, perform a slit lamp examination to assess adequate fit (centration and movement). If fit is acceptable, dispense the lenses instructing the patient to return in one week for reassessment (see PATIENT MANAGEMENT section).
D. Multifocal Troubleshooting
Unacceptable Near Vision:
If it has been determined that no change is required based 
on the over-refraction then add +0.25 D to the spherical power of the non-dominant eye. 
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Unacceptable Distance Vision:
If it has been determined that no change is required based 
on the over-refraction then make the changes as listed below:
‚Ä¢ If the patient is wearing two ‚ÄúLOW‚Äù ADD lenses, change 
the dominant eye to a ACUVUE
¬Æ OASYS (senofilcon A) 
Soft Contact [CONTACT_721573] a power equal to the spherical equivalent distance prescription.
‚Ä¢ If the patient is wearing two ‚ÄúMID‚Äù ADD lenses, change 
the ADD power in the dominant eye to the ‚ÄúLOW‚Äù ADD power.
‚Ä¢ If the patient is wearing a ‚ÄúMID‚Äù ADD lens in the dominant 
eye and a ‚ÄúHGH‚Äù ADD lens in the non-dominant eye, change the non-dominant eye to a ‚ÄúMID‚Äù ADD lens and add +0.25D to the distance power.
Once the changes have been made for the troubleshooting repeat steps 3-6 in section C above (‚ÄúSelect the Initial Trial Lens‚Äù) to assess if the vision is acceptable.
E. Adaptation
Visually demanding situations should be avoided during the initial wearing period. A patient may at first experience some mild blurred vision, dizziness, headaches and a feeling of slight imbalance. You should explain the adaptational symptoms to the patient. These symptoms may last for a brief minute or for several weeks. The longer these symptoms persist, the poorer the prognosis for successful adaptation.
To help in the adaptation process, the patient can be advised to first use the lenses in a comfortable familiar environment such as in the home.
Some patients feel that automobile driving performance may not be optimal during the adaptation process. This is particularly true when driving at night. Before driving a motor vehicle, it may be recommended that the patient be a 
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
passenger first to make sure that their vision is satisfactory
for operating an automobile. During the first several weeksof wear (when adaptation is occurring), it may be advisablefor the patient to only drive during optimal driving conditions.After adaptation and success with these activities, the patientshould be able to drive under other conditions with caution.
All patients should be supplied with a copy of the
PATIENT INSTRUCTION GUIDE for these lenses.Copi[INVESTIGATOR_35461].acuvue.com .
PATIENT MANAGEMENT
‚Ä¢ PROVIDE THE PATIENT WITH A COPY OF THE PATIENT
INSTRUCTION GUIDE FOR THESE LENSES. REVIEWTHESE INSTRUCTIONS WITH THE PATIENT SO THAT HEOR SHE CLEARLY UNDERSTANDS THE PRESCRIBEDWEARING AND REPLACEMENT SCHEDULE (DAILYDISPOSABLE, EXTENDED WEAR, OR FREQUENTREPLACEMENT).
‚Ä¢ Recommend an appropriate cleaning and disinfecting
system and provide the patient with instructions regardingproper lens care. Chemical or hydrogen peroxidedisinfection is recommended.
‚Ä¢ Schedule a follow-up examination.
WEARING SCHEDULE
The wearing schedule should be determined by [CONTACT_721574]. Regular checkups, as determined by [CONTACT_721575], are also extremely important.
For Daily Wear:Patients tend to over wear the lenses initially. The Eye Care
Professional should emphasize the importance of adheringto the initial maximum wearing schedule. Maximum wearingtime should be determined by [CONTACT_721576]‚Äôs physiological eye condition, because
	0 
!&$
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
individual response to contact [CONTACT_35580].
The maximum suggested wearing time for these lenses is:
DAY HOURS
1 6-8
2 8-10
3 10-12
4 12-14
5 and after all waking hours
For Extended Wear:It is recommended that the contact [CONTACT_35560] Ô¨Årst be 
evaluated on a daily wear schedule. If successful, then a gradual introduction of extended wear can be followed as determined by [CONTACT_71187].
These lenses are intended for extended wear up to 6 nights/7 
days of continuous wear. Not all patients can achieve the maximum wear time.
For Therapeutic Lens Wear:Close supervision by [CONTACT_721577]. 
These lenses can be worn for extended wear for up to 6 nights/7 days of continuous wear. The Eye Care Professional should determine the appropriate wearing time and provide speciÔ¨Åc instructions to the patient regarding lens care, insertion, and removal.
REPLACEMENT SCHEDULE
For Lenses Prescribed for Frequent Replacement:
When prescribed for daily wear (frequent replacement), it is 
recommended that the lenses be discarded and replaced with a new lens every 2 weeks. However, the Eye Care Professional is encouraged to determine an appropriate replacement schedule based upon the response of the patient.
For Lenses Prescribed for Single Use Disposable Wear:
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
These lenses are indicated for single use disposable wear and 
should be discarded upon removal.
LENS CARE DIRECTIONS
For Lenses Prescribed for Frequent Replacement Wear:
The Eye Care Professional should review with the patient, lens 
care directions for cleaning, disinfecting and storing, including both basic lens care information and specific instructions on the lens care regimen recommended for the patient.
For Lenses Prescribed for Single Use Disposable Wear:
The Eye Care Professional should review with the patient that 
no cleaning or disinfection is needed with disposable lenses. Patients should always dispose of lenses when they are removed and have replacement lenses or spectacles available. 
Care for a Sticking (Non-Moving) LensDuring removal, if the lens sticks to the eye, the patient should 
be instructed to apply a few drops of the recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to move freely on the eye before removing it. If non-movement of the lens continues after a few minutes, the patient should immediately contact [CONTACT_35578].  
EMERGENCIES
The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY WITH TAP WATER AND IMMEDIATELY CONTACT [CONTACT_35581] A HOSPI[INVESTIGATOR_35466].
HOW SUPPLIED
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Each sterile lens is supplied in a foil-sealed plastic package
containing buffered saline solution with methyl ether cellulose.The plastic package is marked with the following:
‚Ä¢ ACUVUE
¬Æ OASYS MULTIFOCAL : base curve, power,
diameter, ADD, lot number, and expi[INVESTIGATOR_721525]:
[COMPANY_012] Vision Care, Inc.
[ADDRESS_985637]
Jacksonville, FL [ZIP_CODE]
[LOCATION_003]
Tel: [PHONE_564]
www.acuvue.com
	0 
!&$+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 DETERMINATION OF NEAR ADDITION 
 
   
	0 
!&$		+%	
 
Title:                          Determination of Near Addition 
Document Type:        
Document Number:   Revision Number:  5 
Page 1 of 5  
	0 
!&$	
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Determination of Near Addition 
Document Type:        
Document Number:   Revision Number:  5 
Page 2 of 5 
	0 
!&$	+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Determination of Near Addition 
Document Type:        
Document Number:   Revision Number:  5 
Page 3 of 5 
	0 
!&$	+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Determination of Near Addition 
Document Type:        
Document Number:   Revision Number:  5 
Page 4 of 5  
	0 
!&$	
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Determination of Near Addition 
Document Type:        
Document Number:   Revision Number:  5 
Page 5 of 5 
	0 
!&$	+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 LENS FITTING CHARACTERISTICS 
  
	0 
!&$	+%	
 
Title:                          Lens Fitting Characteristics 
Document Type:        
Document Number:   Revision Number:  6 
Page 1 of 5 
	0 
!&$	+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Lens Fitting Characteristics 
Document Type:        
Document Number:   Revision Number:  6 
Page 2 of 5 
	0 
!&$	+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Lens Fitting Characteristics 
Document Type:        
Document Number:   Revision Number:  6 
Page 3 of 5  
 
 
    
 
  
 
  
 
     
 
   
 
 
 
   
 
	0 
!&$		+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Lens Fitting Characteristics 
Document Type:        
Document Number:   Revision Number:  6 
Page 4 of 5  
 
 
 
     
 
	0 
!&$			+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Lens Fitting Characteristics 
Document Type:        
Document Number:   Revision Number:  6 
Page 5 of 5  
 
 
 
 
 
	0 
!&$		
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 SUBJECT REPORTED OCULAR SYMPTOMS 
  
	0 
!&$		+%	
 
Title:                          Subject Reported Ocular Symptoms/Problems 
Document Type:        
Document Number:   Revision Number:  4 
Page 1 of 1  
 
                   
  
	0 
!&$		+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTION 
  
	0 
!&$		
+%	
 
Title:                           De termination of Distance Spherocylindrical Refractive Error 
Document Type:         
Document Number:   Revision Number:  5 
Page 1 of 5 
	0 
!&$		+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                           De termination of Distance Spherocylindrical Refractive Error 
Document Type:         
Document Number:   Revision Number:  5 
Page 2 of 5  
 
	0 
!&$		+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                           De termination of Distance Spherocylindrical Refractive Error 
Document Type:         
Document Number:   Revision Number:  5 
Page 3 of 5 
	0 
!&$		+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                           De termination of Distance Spherocylindrical Refractive Error 
Document Type:         
Document Number:   Revision Number:  5 
Page 4 of 5 
	0 
!&$		+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
BIOMICROSCOPY SCALE 
  
	0 
!&$	
	+%	
 
Title:      Biomicroscopy Scale 
Document Type:  
Document Number:       Revision Number:  10 
 
 
	0 
!&$	

+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:      Biomicroscopy Scale 
Document Type:  
Document Number:       Revision Number:  10 
 
	0 
!&$	
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:      Biomicroscopy Scale 
Document Type:  
Document Number:       Revision Number:  10 
 
	0 
!&$	
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:      Biomicroscopy Scale 
Document Type:  
Document Number:       Revision Number:  10 
 
	0 
!&$	

+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:      Biomicroscopy Scale 
Document Type:  
Document Number:       Revision Number:  10 
 
Page 5 of 5  
 
	0 
!&$	
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION 
  
	0 
!&$	
+%	
 
Title:                          Distance and Near Snellen Visual Acuity Evaluation 
Document Type:        
Document Number:   Revision Number:  5 
Page 2 of 4 
	0 
!&$	
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Distance and Near Snellen Visual Acuity Evaluation 
Document Type:        
Document Number:   Revision Number:  5 
Page 3 of 4  
 
 
  
 
 
 
     
 
  
 
 
 
  
	0 
!&$	+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Title:                          Distance and Near Snellen Visual Acuity Evaluation 
Document Type:        
Document Number:   Revision Number:  5 
Page 4 of 4  
     
 
 
  
  
 
  
 
  
 
  
 
    
 
  
  
 
 
	0 
!&$		+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX E:  OCULAR DOMINANCE 
	0 
!&$	
+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX F:  IRIS COLOR SCALE 
 
  
	0 
!&$	+%	
 
 
  
	0 
!&$	+%	
 )(*("!)./#1,+.+"+)
+'*-+*+'*-+* (-(+*!,$*"
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX G:  TEST AND CONTROL LENS FITTING GUIDE 
	0 
!&$	
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX H:  PSYCHOPHYSICAL TESTING  
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
	0 
!&$	+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
	0 
!&$		+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX I: GUIDELINES FOR COVID-19 RISK MITIGATION 
  
	0 
!&$	
+%	
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_169778]: CR-[ADDRESS_985638] Lens Designs with and without 
an HEV-Blocker on Visual Function 
 
Version and Date: 4.[ADDRESS_985639] this study according to ISO [ZIP_CODE]:2020,
1 GCP and ICH guidelines,2 the Declaration 
of Helsinki,3 [LOCATION_002] (US) Code of Federal Regulations (CFR),4 and the pertinent individual 
country laws/regulations and to comply with its obligations, subject to ethical and safety considerations. 
The Principal Investigator [INVESTIGATOR_19539], including Sub-Investigators adhere to all ICH
[ADDRESS_985640] (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. 
 
I am responsible for ensuring that all clinical site personnel including Sub-Investigators adhere to all 
ICH
[ADDRESS_985641] read the suggested guidance provided by [CONTACT_19610]-19 risk mitigation, 
(COVID-19 Work Instruction in the Appendix I of th is protocol). I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID-19 risks. 
 
Principal 
Investigator:    
 [INVESTIGATOR_197532] (Printed)   
Institution/Site:  
   
 Institution/Site Name 
 
  
  
 [CONTACT_16277]/Site Address   
 
	0 
!&$	
+%	
 